[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 296
1. Mader AM, Patrício FR, Rigueiro MP, Lourenço LG: [Analysis of clinicopathological, tumor cell proliferation and apoptosis parameters in adenocarcinoma of the gastric cardia]. Arq Gastroenterol; 2006 Jul-Sep;43(3):184-90
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of clinicopathological, tumor cell proliferation and apoptosis parameters in adenocarcinoma of the gastric cardia].
  • [Transliterated title] Estudo clínico-patológico, da proliferação celular e da apoptose no adenocarcinoma gástrico da cárdia.
  • BACKGROUND/AIMS: In view of the increased incidence of carcinoma of the cardia over recent years, this work had the aim of studying the clinicopathological aspects, cell proliferative and tumor apoptotic indices of this neoplasm, their interrelations and possible influences on the prognosis.
  • MATERIAL AND METHODS: Forty cases of adenocarcinoma of the cardia were studied between 1988 and 2001, with a minimum clinical follow-up of 3 years.
  • Gender; age, Laurén and Ming histological type, staging, and the presence or absence of intestinal metaplasia, epithelial dysplasia and Helicobacter pylori in the adjacent mucosa were analyzed.
  • There was predominance of the male gender (72.5%), diffuse histological type (55%) and infiltrative histological type (72.5%), and the more advanced stages (III and IV: 67.5%).
  • There was a positive correlation for intestinal histological type with PCNA and apoptotic indices, in 10 high power fields.
  • CONCLUSIONS: Adenocarcinoma of the cardia predominated in male adults of mean age 61 years, and the predominant type was diffuse in more advanced stages.
  • Survival in cases of adenocarcinoma of the cardia is still low.
  • [MeSH-major] Adenocarcinoma / pathology. Apoptosis. Cardia / pathology. Cell Proliferation. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17160232.001).
  • [ISSN] 0004-2803
  • [Journal-full-title] Arquivos de gastroenterologia
  • [ISO-abbreviation] Arq Gastroenterol
  • [Language] por
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Proliferating Cell Nuclear Antigen
  •  go-up   go-down


2. Fan Z, Li J, Dong B, Huang X: Expression of Cdx2 and hepatocyte antigen in gastric carcinoma: correlation with histologic type and implications for prognosis. Clin Cancer Res; 2005 Sep 1;11(17):6162-70
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of Cdx2 and hepatocyte antigen in gastric carcinoma: correlation with histologic type and implications for prognosis.
  • PURPOSE: This study was designed to (a) analyze the correlation between the expression of Cdx2 and Hep and the clinicopathologic features of patients with gastric carcinoma, and (b) determine the value of combined analysis of Cdx2 and Hep expression in distinguishing histologic types and prognoses of gastric carcinomas.
  • EXPERIMENTAL DESIGN: The expression of Cdx2 and Hep were studied using immunohistochemistry of paraffin-embedded tumor specimens from 109 patients who underwent D2 resection for gastric adenocarcinoma from 1995 to 1998.
  • RESULTS: Nuclear Cdx2 and Hep expression was detected in 36.7% (40 of 109) and 54.1% (59 of 109) of gastric carcinoma cases, respectively.
  • Expression of Cdx2 and Hep was significantly higher in intestinal-type carcinomas than in diffuse-type carcinomas (P = 0.027 and P = 0.037, respectively).
  • Multivariate analysis revealed that the expression of Cdx2 and Hep were independent prognostic indicators of gastric carcinoma.
  • The combination of Cdx2 and Hep expression was significantly lower in diffuse-type carcinoma than in intestinal or mixed-type carcinoma.
  • Multivariate analysis revealed that Cdx2 and Hep expression was an independent prognostic indicator of gastric carcinoma (P < 0.001).
  • CONCLUSIONS: These data suggest that combined analysis of Cdx2 and Hep has significant value in distinguishing histologic types and in predicting the prognosis of gastric carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16144916.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Homeodomain Proteins; 0 / Trans-Activators; 156560-97-3 / Cdx-2-3 protein
  •  go-up   go-down


3. Calcagno DQ, Guimarães AC, Leal MF, Seabra AD, Khayat AS, Pontes TB, Assumpção PP, De Arruda Cardoso Smith M, Burbano RR: MYC insertions in diffuse-type gastric adenocarcinoma. Anticancer Res; 2009 Jul;29(7):2479-83
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MYC insertions in diffuse-type gastric adenocarcinoma.
  • MATERIALS AND METHODS: MYC copy number and its insertion, as well as the chromosomes in which MYC was inserted, were evaluated by fluorescence in situ hybridization assay in interphase and metaphase cells of 12 diffuse-type gastric cancer samples.
  • MYC insertion and cytoplasmatic immunoreactivity may be a common characteristic of diffuse-type gastric cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Genes, myc. Stomach Neoplasms / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19596917.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  •  go-up   go-down


Advertisement
4. Lomo L, Nucci MR, Lee KR, Lin MC, Hirsch MS, Crum CP, Mutter GL: Histologic and immunohistochemical decision-making in endometrial adenocarcinoma. Mod Pathol; 2008 Aug;21(8):937-42
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histologic and immunohistochemical decision-making in endometrial adenocarcinoma.
  • Diffuse p53 immunostaining distinguishes 85% of serous (Type II) from endometrioid (Type I) carcinomas and is an independent marker for poor prognosis.
  • Because p53 is an important marker for endometrial adenocarcinoma outcome, and cannot be predicted in advance in indeterminate cases, p53 immunostaining should be employed in cases with observer disagreement in a binary system.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18500258.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


5. Adán-Merino L, Gómez-Senent S, Froilán-Torres C, Suárez J, Martín- Arranz E, Larrauri J, Mora-Sanz P, Segura-Cabral JM, Aldeguer-Martinez M: [Gastric adenocarcinoma in young adults; comparative study with older patients]. Rev Gastroenterol Mex; 2010;75(3):253-60
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gastric adenocarcinoma in young adults; comparative study with older patients].
  • [Transliterated title] Adenocarcinoma gástrico en adultos jóvenes; estudio comparativo con pacientes mayores.
  • BACKGROUND: Gastric adenocarcinoma (GA) has been considered a disease of elderly age and has been rarely reported in patients younger than 35 years of age.
  • Lauren diffuse type carcinoma was more frequent in people younger than 35 years (70%) than in older patients (17.4%).
  • CONCLUSION: Gastric adenocarcinoma is rare in young patients and most cases presented at advanced clinical stage similar to elderly patients, so the prognosis in both age groups is poor.
  • [MeSH-major] Adenocarcinoma / epidemiology. Stomach Neoplasms / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20959173.001).
  • [ISSN] 0375-0906
  • [Journal-full-title] Revista de gastroenterología de México
  • [ISO-abbreviation] Rev Gastroenterol Mex
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


6. Garfield DH, Cadranel JL, Wislez M, Franklin WA, Hirsch FR: The bronchioloalveolar carcinoma and peripheral adenocarcinoma spectrum of diseases. J Thorac Oncol; 2006 May;1(4):344-59
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The bronchioloalveolar carcinoma and peripheral adenocarcinoma spectrum of diseases.
  • Bronchioloalveolar carcinoma (BAC) develops from terminal bronchiolar and acinar epithelia, growing along alveolar septa but without evidence of vascular or pleural involvement.
  • Problematically, BAC may exhibit multifocal involvement by means of diffuse aerogenous metastatic spread, making this definition inapplicable for patients with stage IIIB to IV disease from whom only small size biopsy or cytological specimens are obtained.
  • The recent interest and potential importance of BAC and the related peripheral adenocarcinoma (ADC), mixed subtype, is attributable to mounting evidence that some, perhaps many, of what are called peripheral ADCs have arisen from and often contain BAC.
  • These include frequent female occurrence, especially in East Asians; no or less smoking history; an often indolent course; distinctive chest computed tomographic findings; frequent presentation as an asymptomatic, sometimes small, peripheral nodule(s)/mass; multifocal/synchronous primary tumors; and less frequently as pneumonic-type consolidation or diffuse, inoperable lesions, the latter two often with bronchorrhea, and with chest-only disease.
  • [MeSH-major] Adenocarcinoma / therapy. Adenocarcinoma, Bronchiolo-Alveolar / therapy. Lung Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Thorac Oncol. 2006 Jun;1(5):405
  • (PMID = 17409882.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA 058187
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 207
  •  go-up   go-down


7. Bal N, Yildirim S, Nursal TZ, Bolat F, Kayaselcuk F: Association of ezrin expression in intestinal and diffuse gastric carcinoma with clinicopathological parameters and tumor type. World J Gastroenterol; 2007 Jul 21;13(27):3726-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of ezrin expression in intestinal and diffuse gastric carcinoma with clinicopathological parameters and tumor type.
  • AIM: To investigate the correlation between ezrin expression and types of gastric carcinoma and clinico-pathological variables.
  • METHODS: We examined ezrin protein expression in 75 gastric carcinoma (53 intestinal types of adenocarcinoma, 22 diffuse types of carcinoma) tissues by immunohistochemistry.
  • The results were compared with clinicopathological parameters such as tumor type, grade of tumor, clinical stage, presence of metastatic lymph node, and depth of invasion.
  • RESULTS: Ezrin immunostaining was positive in 43 cases (81.1%) of intestinal type and in 9 (40.9%) cases of diffuse type adenocarcinomas (P < 0.001).
  • CONCLUSION: The low expression of ezrin implicates the loss of adhesion in diffuse carcinomas.
  • Furthermore, overexpression of ezrin in carcinomas with H pylori infection may be a genuine specific pathway in which H pylori may cause/initiate gastric carcinoma.
  • [MeSH-major] Adenocarcinoma / chemistry. Cytoskeletal Proteins / analysis. Stomach Neoplasms / chemistry

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17659733.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cytoskeletal Proteins; 0 / ezrin
  • [Other-IDs] NLM/ PMC4250645
  •  go-up   go-down


8. Sezeur A, Schielke A, Larue L, Fléjou JF: [Hereditary diffuse gastric cancer]. Gastroenterol Clin Biol; 2006 Oct;30(10):1205-13
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hereditary diffuse gastric cancer].
  • Some diffuse type gastric cancers are of hereditary origin.
  • Because of serious prognosis of symptomatic hereditary diffuse gastric cancer (HDGC), the high penetrance of the gene (67% in men and 83% in women) and the young age of onset of these tumors (before the age of 40), a prophylactic gastrectomy is recommended to the mutation carriers.
  • [MeSH-major] Adenocarcinoma / genetics. Carcinoma, Signet Ring Cell / genetics. Neoplastic Syndromes, Hereditary / genetics. Stomach Neoplasms / genetics


9. Pianzola HM, Ottino A: ["Glassy - cell" like adenocarcinoma: a new variant of gastric tumor]. Acta Gastroenterol Latinoam; 2006 Dec;36(4):205-10
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ["Glassy - cell" like adenocarcinoma: a new variant of gastric tumor].
  • [Transliterated title] Adenocarcinoma de tipo glassy - cell: una nueva variante de tumor gástrico.
  • Most gastric malignancies correspond histologically to adenocarcinomas, either of the intestinal or diffuse type, other tumoral varieties being much less frequent.
  • We report a case of a malignant epithelial tumor, whose histological and cytological characteristics correspond to an unusual, although well defined entity, which may appear in the cervix and less frequently in the endometrium, known as adenocarcinoma of the glassy - cell variety.
  • [MeSH-major] Adenocarcinoma / pathology. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17225449.001).
  • [ISSN] 0300-9033
  • [Journal-full-title] Acta gastroenterologica Latinoamericana
  • [ISO-abbreviation] Acta Gastroenterol. Latinoam.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Argentina
  •  go-up   go-down


10. Kim JY, Park DY, Kim GH, Choi KU, Lee CH, Huh GY, Sol MY, Song GA, Jeon TY, Kim DH, Sim MS: Smad4 expression in gastric adenoma and adenocarcinoma: frequent loss of expression in diffuse type of gastric adenocarcinoma. Histol Histopathol; 2005 04;20(2):543-9
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Smad4 expression in gastric adenoma and adenocarcinoma: frequent loss of expression in diffuse type of gastric adenocarcinoma.
  • The purpose of this study was to elucidate Smad4 expression and localization in 65 gastric adenomas, 49 intestinal-type and 39 diffuse type of gastric adenocarcinomas (including 12 cases of fresh frozen tissue) using Real-time RT-PCR and immunohistochemistry.
  • Real-time RT-PCR showed that intestinal type gastric adenocarcinomas have higher Smad4 mRNA expression than diffuse type gastric adenocarcinomas.
  • Immunohistochemical stain for Smad4 revealed that expression of Smad4 was significantly lower in diffuse-type gastric adenocarcinoma than intestinal-type gastric adenocarcinomas.
  • Also, higher Smad4 protein expression in intestinal type gastric adenocarcinomas than overall gastric adenoma was noted.
  • These results suggest that Smad4 might play different roles in human gastric carcinogenesis, especially between intestinal type and diffuse type of gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenoma / genetics. Adenoma / metabolism. DNA-Binding Proteins / genetics. DNA-Binding Proteins / metabolism. Stomach Neoplasms / genetics. Stomach Neoplasms / metabolism. Trans-Activators / genetics. Trans-Activators / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15736060.001).
  • [ISSN] 0213-3911
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / SMAD4 protein, human; 0 / Smad4 Protein; 0 / Trans-Activators; 0 / Transforming Growth Factor beta
  •  go-up   go-down


11. Chou YY, Jeng YM, Lee TT, Hu FC, Kao HL, Lin WC, Lai PL, Hu RH, Yuan RH: Cytoplasmic CD24 expression is a novel prognostic factor in diffuse-type gastric adenocarcinoma. Ann Surg Oncol; 2007 Oct;14(10):2748-58
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoplasmic CD24 expression is a novel prognostic factor in diffuse-type gastric adenocarcinoma.
  • However, the role of CD24 in gastric adenocarcinoma remains largely unknown.
  • METHODS: The expression pattern of CD24 in 103 gastric adenocarcinomas (31 diffuse type, 60 intestinal type, and 12 mixed type) was analyzed by immunohistochemistry.
  • RESULTS: Cytoplasmic CD24 expression occurred in 50% of the gastric adenocarcinoma patients and was associated with high-stage tumor (Stage III-IV, P = .023), serosal invasion (SI, P = .010), lymphovascular invasion (LVI, P = .039), and lower 10-year survival (P = .0238).
  • The CD24 staining pattern was different in intestinal and diffuse-type gastric adenocarcinomas.
  • Further analysis showed that cytoplasmic CD24 expression was, in fact, correlated with high-stage tumor, SI, LVI, and lower 10-year survival significantly (P = .020, P = .007, P = .018, P = .0285, respectively) in diffuse-type gastric adenocarcinoma.
  • Moreover, multivariate analysis showed that cytoplasmic CD24 expression was an independent risk factor of SI and LVI respectively (P = .0083 and P = .0019), and thus it contributed to high-stage tumor and poor patient survival in diffuse- or mixed-type gastric adenocarcinoma.
  • CONCLUSIONS: Cytoplasmic expression of CD24 was associated with invasiveness and poorer prognosis and can serve as a novel target for prognostic prediction and adjuvant treatment of patients with diffuse-type gastric adenocarcinoma after tumor resection.
  • [MeSH-major] Adenocarcinoma / pathology. Antigens, CD24 / analysis. Biomarkers, Tumor / analysis. Cytoplasm / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17680316.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD24; 0 / Biomarkers, Tumor
  •  go-up   go-down


12. Khalil KF, Saeed W, Zill-e-Hamayun: Diffuse consolidation form of bronchoalveolar carcinoma. J Coll Physicians Surg Pak; 2010 Mar;20(3):216-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse consolidation form of bronchoalveolar carcinoma.
  • This case report describes a patient with diffuse consolidation form of bronchoalveolar carcinoma (BAC) which is a rare type of adenocarcinoma of lung.
  • Traditionally, diffuse consolidation is the radiological presentation in only 20% of patients with bronchoalveolar carcinoma.
  • [MeSH-major] Adenocarcinoma / therapy. Lung Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20392391.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


13. Morris LE, Bloom GS, Frierson HF Jr, Powell SM: Nucleotide variants within the IQGAP1 gene in diffuse-type gastric cancers. Genes Chromosomes Cancer; 2005 Mar;42(3):280-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nucleotide variants within the IQGAP1 gene in diffuse-type gastric cancers.
  • The histopathologic appearance of diffuse gastric carcinoma is defined by non- or poorly cohesive tumor cells, indicating abnormal intercellular adhesion.
  • In 2 of the 33 diffuse gastric cancers, there was a missense nucleotide change predicted to alter the amino acid sequence in the GAP-related domain, which includes part of the binding site for the activated small G proteins Cdc42 and Rac1.
  • Many intronic IQGAP1 gene changes were observed, and several occurred more frequently in diffuse-type gastric cancers than in intestinal-type gastric cancers.
  • The most expanded six-repeat sequence was present exclusively in diffuse-type gastric cancers.
  • Additionally, 19 diffuse cases and two intestinal cases exhibited silent coding region nucleotide alterations.
  • Taken together, our results suggest that IQGAP1 coding sequence mutations are not a frequent event in gastric cancer, but do occur in a subset of diffuse-type gastric carcinomas.
  • Additional studies analyzing other proteins involved in cell adhesion may lead to a better molecular understanding of the histopathologic appearance of diffuse gastric cancers.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Animals. Humans. Introns / genetics. Mice. Mice, SCID. Stomach / metabolism. Stomach / pathology. Transplantation, Heterologous

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15611933.001).
  • [ISSN] 1045-2257
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA67900; United States / NINDS NIH HHS / NS / NS530485
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / IQ motif containing GTPase activating protein 1; 0 / ras GTPase-Activating Proteins
  •  go-up   go-down


14. Giaginis CT, Vgenopoulou S, Tsourouflis GS, Politi EN, Kouraklis GP, Theocharis SE: Expression and clinical significance of focal adhesion kinase in the two distinct histological types, intestinal and diffuse, of human gastric adenocarcinoma. Pathol Oncol Res; 2009 Jun;15(2):173-81
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and clinical significance of focal adhesion kinase in the two distinct histological types, intestinal and diffuse, of human gastric adenocarcinoma.
  • FAK expression was assessed immunohistochemically in tumoral samples of 66 gastric adenocarcinoma cases, 30 intestinal and 36 diffuse type, and was statistically analyzed in relation to various clinicopathological characteristics, tumor proliferative capacity and patients' survival.
  • In intestinal type carcinomas, enhanced FAK expression was significantly associated with increased tumor proliferative capacity (P = 0.012).
  • In diffuse type carcinomas, FAK staining intensity was significantly correlated with tumor size (P = 0.026) and disease stage (P = 0.024), presenting also a borderline association with nodal status (P = 0.053).
  • In diffuse type carcinomas, enhanced FAK expression was significantly associated with longer overall survival times (log-rank test, P = 0.014), being also identified as an independent prognostic factor in multivariate analysis (Cox regression, P = 0.016).
  • In contrast, patients with intestinal type tumors and enhanced FAK expression were characterized by shorter overall survival times, without though reaching statistical significance (log-rank test, P = 0.092).
  • [MeSH-major] Adenocarcinoma / enzymology. Biomarkers, Tumor / metabolism. Focal Adhesion Protein-Tyrosine Kinases / metabolism. Intestinal Neoplasms / enzymology. Stomach Neoplasms / enzymology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18987997.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.2 / Focal Adhesion Protein-Tyrosine Kinases
  •  go-up   go-down


15. Ajani JA, Rodriquez W, Bodoky G, Moiseyenko V, Lichinitser M, Gorbunova V, Vynnychenko I, Garin A, Lang I, Falcon S: Multicenter phase III comparison of cisplatin/S-1 (CS) with cisplatin/5-FU (CF) as first-line therapy in patients with advanced gastric cancer (FLAGS): Secondary and subset analyses. J Clin Oncol; 2009 May 20;27(15_suppl):4511

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: 1,053 (1,029 treated; CS=521/CF=508) patients with untreated, advanced gastric/gastroesophageal adenocarcinoma were randomized to either S-1 (25 mg/m<sup>2</sup> bid, d 1-21)/cisplatin (75 mg/m<sup>2</sup> d 1) q 28 d or 5-FU (1,000 mg/m<sup>2</sup>/d 5-d infusion)/cisplatin (100 mg/m<sup>2</sup> d 1) q 28 d.
  • OS analyses for non-inferiority (NI), by pre-specified stratifications, and by the largest histologic subset (diffuse type histology) were performed.
  • Subset analysis: OS analysis for diffuse type histology (n=590) showed that CS (median survival=9.0 months) resulted in a superior OS (Log rank p=0.0413; HR, 0.83 [95% CI, 0.70 to 0.99]) than CF (median survival=7.1 months).
  • CS resulted in a HR=<1.0 in the majority of pre-specified stratifications and CS produced statistically superior OS for patients with diffuse type histology (needs prospective studies).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962707.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Tsuburaya A, Narahara H, Imamura H, Hatake K, Imamoto H, Esaki T, Kato M, Furukawa H, Hamada C, Sakata Y, GC0301/TOP-002 Study Group: Updated result on the 2.5-year follow-up of GC0301/TOP-002: Randomized phase III study of irinotecan plus S-1 (IRI-S) versus S-1 alone as first-line treatment for advanced gastric cancer (AGC). J Clin Oncol; 2009 May 20;27(15_suppl):4544

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The HR of diffuse type group was 0.71 (95%Cl: 0.52-0.96), and of PS1, 2 group was 0.63 (95%Cl: 0.42-0.95).
  • According to exploratory analyses, IRI-S may have clinical benefit in early-term of treatment, group of the diffuse type and that of PS1, 2.
  • We need more considering predictive factors, because the gastric cancer is heterogeneous adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963013.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Efremidis AP, Fostira F, Panopoulos C, Papademitriou K, Pistalmazian N, Tsoukalas N, Yannoukakos D: CDH-1 germ line mutations in diffuse gastric and infiltrating ductal breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e22218

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CDH-1 germ line mutations in diffuse gastric and infiltrating ductal breast cancer.
  • : e22218 Background: Hereditary Diffuse Gastric Cancer (HDGC) syndrome is characterized by the predisposition to gastric cancer of the diffuse type and to breast cancer of the lobular type.
  • The median age of onset for diffuse gastric cancer is 38 years.
  • CDH1 mutations are highly penetrant, conferring a cumulative risk of diffuse gastric cancer of 75%.
  • She underwent bilateral mastectomy for an infiltrating ductal adenocarcinoma of the left breast and in situ lobular of the right breast.
  • At the age of 45 the patient underwent gastrectomy for diffuse type gastric adenocarcinoma.
  • She had a positive family history for breast and gastric cancer from both sides, but without meeting the absolute clinical criteria for hereditary diffuse gastric cancer syndrome.
  • Criteria should be more flexible in respects to the histopathology of the cancer type.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964173.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Amico P, Greco P: Diffuse and extreme vacuolization of tumour cells in rectal adenocarcinoma after neoadjuvant therapy: an unusual finding. Pathologica; 2010 Oct;102(5):414-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse and extreme vacuolization of tumour cells in rectal adenocarcinoma after neoadjuvant therapy: an unusual finding.
  • We report a case of diffuse and extreme cytoplasmic vacuolization of tumour cells in a rectal adenocarcinoma after neoadjuvant treatment.
  • A 64-year-old man with a moderately differentiated rectal adenocarcinoma, diagnosed by endoscopic rectal biopsy, underwent surgical treatment after chemoradiotherapy.
  • Residual tumour mass was represented by foci of neoplastic cells with the morphological features of conventional type adenocarcinoma, and surprisingly, by numerous areas consisting of several giant vacuoles, variable in size, merging to form multilocular spaces separated by a rim of cell membrane with a "plant-like" appearance.
  • [MeSH-major] Adenocarcinoma / pathology. Cytoplasm / pathology. Rectal Neoplasms / pathology. Vacuoles / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21361123.001).
  • [ISSN] 0031-2983
  • [Journal-full-title] Pathologica
  • [ISO-abbreviation] Pathologica
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


19. Kuroda T, Ito M, Wada Y, Kitadai Y, Tanaka S, Yoshida K, Yoshihara M, Haruma K, Merdh S, Chayama K: Presence of poorly differentiated component correlated with submucosal invasion in the early diffuse-type gastric cancer. Hepatogastroenterology; 2008 Nov-Dec;55(88):2264-8
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Presence of poorly differentiated component correlated with submucosal invasion in the early diffuse-type gastric cancer.
  • BACKGROUND/AIMS: Diffuse-type gastric carcinoma is associated with a poor prognosis.
  • However, the clinical behavior of diffuse-type gastric cancer is not fully understood.
  • The aim of this study is to distinguish the behaviors of early diffuse-type gastric carcinomas by sub classifying tumors according to their histologic features.
  • METHODOLOGY: A total of 114 cases of diffuse-type early gastric cancer were studied retrospectively.
  • We analyzed and compared the resected cancer specimens according to the histologic components: as poorly differentiated adenocarcinoma component-present (poor+) versus poorly differentiated adenocarcinoma component-absent (poor-).
  • CONCLUSIONS: The biologic behavior of poor+ gastric carcinoma is worse than that of poor- carcinoma.
  • There is a close relation between H. pylori infection and carcinogenesis of poorly differentiated adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Stomach Neoplasms / pathology

  • Genetic Alliance. consumer health - Signet ring cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19260519.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Gastrins
  •  go-up   go-down


20. Zhang XQ, Yang YQ, Liu BY, Jin XL, Li W, Tang KL, Zhang QH, Lin YZ, Zhu ZG: [Gene expression profiling of diffuse-type gastric cancer by cDNA microarray]. Zhonghua Zhong Liu Za Zhi; 2006 Feb;28(2):116-9
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gene expression profiling of diffuse-type gastric cancer by cDNA microarray].
  • OBJECTIVE: To identify cancer-related genes in diffuse-type gastric cancer and to explore its molecular mechanism by cDNA microarray analysis.
  • METHODS: A total of 22 pairs of diffuse-type gastric cancer tissue and the corresponding normal mucosa were taken and freshly frozen. cDNA microarray with 14,592 genes/ESTs was used.
  • RESULTS: Compared with those of corresponding normal mucosa, there were a total of 153 genes/ESTs up-regulated and 204 down-regulated in diffuse-type gastric cancer.
  • CONCLUSION: Gene expression profiling by cDNA microarray analysis provides not only molecular understanding of biological properties of cancer, but may also be helpful in discovering new diagnostic markers and therapeutic targets in gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Expressed Sequence Tags. Gene Expression Profiling. Oligonucleotide Array Sequence Analysis. Stomach Neoplasms / genetics
  • [MeSH-minor] Biglycan. Collagen Type I / metabolism. Extracellular Matrix Proteins / metabolism. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Microfilament Proteins / metabolism. Middle Aged. Muscle Proteins / metabolism. Neoplasm Staging. Pepsinogen C / metabolism. Proteoglycans / metabolism

  • Genetic Alliance. consumer health - Signet ring cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16750015.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / BGN protein, human; 0 / Biglycan; 0 / Collagen Type I; 0 / Extracellular Matrix Proteins; 0 / Microfilament Proteins; 0 / Muscle Proteins; 0 / Proteoglycans; 0 / transgelin; 61536-72-9 / Pepsinogen C
  •  go-up   go-down


21. Kanechorn Na Ayuthaya R, Patthamapasphong N, Sura T, Niumpradit N, Trachoo O: Ehlers-Danlos syndrome type IV with gastric adenocarcinoma. J Med Assoc Thai; 2008;91 Suppl 1:S166-71
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ehlers-Danlos syndrome type IV with gastric adenocarcinoma.
  • The vascular type (type IV) is characterized by thin, translucent skin, easy bruising, characteristic facial appearance, and arterial, intestinal, and/or uterine fragility.
  • A first case of EDS type IV with adeno-carcinoma of the stomach in Thailand was reported and literature was reviewed.
  • Abdominal aortic aneurysm were detected with upper gastrointestinal hemorrhage, esophagogastroduodenoscopy showed diffuse gastric body swelling and erythema resulting in chronic gastritis.
  • Gastric biopsy was indicative of adenocarcinoma of the stomach and gastrectomy was done.
  • A vascular EDS type IV was diagnosed.
  • [MeSH-major] Adenocarcinoma / complications. Ehlers-Danlos Syndrome / etiology. Stomach Neoplasms / complications
  • [MeSH-minor] Collagen Type III / genetics. Fatal Outcome. Gastrectomy. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Ehlers-Danlos syndrome.
  • MedlinePlus Health Information. consumer health - Ehlers-Danlos Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18672610.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / COL3A1 protein, human; 0 / Collagen Type III
  •  go-up   go-down


22. Study Group of Millennium Genome Project for Cancer, Sakamoto H, Yoshimura K, Saeki N, Katai H, Shimoda T, Matsuno Y, Saito D, Sugimura H, Tanioka F, Kato S, Matsukura N, Matsuda N, Nakamura T, Hyodo I, Nishina T, Yasui W, Hirose H, Hayashi M, Toshiro E, Ohnami S, Sekine A, Sato Y, Totsuka H, Ando M, Takemura R, Takahashi Y, Ohdaira M, Aoki K, Honmyo I, Chiku S, Aoyagi K, Sasaki H, Ohnami S, Yanagihara K, Yoon KA, Kook MC, Lee YS, Park SR, Kim CG, Choi IJ, Yoshida T, Nakamura Y, Hirohashi S: Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer. Nat Genet; 2008 Jun;40(6):730-40
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer.
  • Gastric cancer is classified into intestinal and diffuse types, the latter including a highly malignant form, linitis plastica.
  • A two-stage genome-wide association study (stage 1: 85,576 SNPs on 188 cases and 752 references; stage 2: 2,753 SNPs on 749 cases and 750 controls) in Japan identified a significant association between an intronic SNP (rs2976392) in PSCA (prostate stem cell antigen) and diffuse-type gastric cancer (allele-specific odds ratio (OR) = 1.62, 95% CI = 1.38-1.89, P = 1.11 x 10(-9)).
  • The association was far less significant in intestinal-type gastric cancer.
  • The same risk allele was also significantly associated with diffuse-type gastric cancer in 457 cases and 390 controls in Korea (allele-specific OR = 1.90, 95% CI = 1.56-2.33, P = 8.01 x 10(-11)).
  • The polymorphism of the PSCA gene, which is possibly involved in regulating gastric epithelial-cell proliferation, influences susceptibility to diffuse-type gastric cancer.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / pathology. Animals. Antigens, Neoplasm. CHO Cells. Carcinoma, Papillary / genetics. Carcinoma, Papillary / pathology. Carcinoma, Signet Ring Cell / genetics. Carcinoma, Signet Ring Cell / pathology. Case-Control Studies. Cell Proliferation. Cricetinae. Cricetulus. Epithelium. Exons / genetics. GPI-Linked Proteins. Gene Frequency. Haplotypes / genetics. Humans. Immunoenzyme Techniques. Intestinal Neoplasms. Japan. Korea. Linkage Disequilibrium. Mice. Odds Ratio. Promoter Regions, Genetic. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Transcription, Genetic

  • Genetic Alliance. consumer health - Signet ring cell carcinoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18488030.001).
  • [ISSN] 1546-1718
  • [Journal-full-title] Nature genetics
  • [ISO-abbreviation] Nat. Genet.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / Neoplasm Proteins; 0 / PSCA protein, human; 0 / RNA, Messenger
  •  go-up   go-down


23. Takeno SS, Leal MF, Lisboa LC, Lipay MV, Khayat AS, Assumpção PP, Burbano RR, Smith Mde A: Genomic alterations in diffuse-type gastric cancer as shown by high-resolution comparative genomic hybridization. Cancer Genet Cytogenet; 2009 Apr 1;190(1):1-7
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genomic alterations in diffuse-type gastric cancer as shown by high-resolution comparative genomic hybridization.
  • Gastric adenocarcinoma is a serious public health concern, especially in northern Brazil.
  • Gastric cancer can be subdivided into diffuse and intestinal types.
  • Genetic imbalances in diffuse-type gastric cancer remain largely unknown.
  • In the present study, we analyzed 24 advanced diffuse-type gastric cancer samples from northern Brazil subjects using high-resolution comparative genomic hybridization.
  • Loss of 11q and 18q were the most frequent chromosomal changes in diffuse-type gastric adenocarcinoma in individuals from northern Brazil.
  • [MeSH-major] Adenocarcinoma / genetics. Chromosome Aberrations. Comparative Genomic Hybridization / methods. Stomach Neoplasms / genetics

  • Genetic Alliance. consumer health - Signet ring cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19264226.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


24. Chandanos E, Rubio CA, Lindblad M, Jia C, Tsolakis AV, Warner M, Gustafsson JA, Lagergren J: Endogenous estrogen exposure in relation to distribution of histological type and estrogen receptors in gastric adenocarcinoma. Gastric Cancer; 2008;11(3):168-74
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endogenous estrogen exposure in relation to distribution of histological type and estrogen receptors in gastric adenocarcinoma.
  • BACKGROUND: Estrogen might protect women against gastric adenocarcinoma of the intestinal histological type.
  • METHODS: A population-based cohort of patients with gastric adenocarcinoma diagnosed in 1958-2004 in the county of Stockholm was identified through the Swedish Cancer Register.
  • Tumor specimens were reviewed, and 289 cases were classified into intestinal (n=101) or diffuse type (n=188).
  • RESULTS: Compared to "exposed women", the intestinal type of gastric adenocarcinoma was more than four times more common among "unexposed men" (odds ratio [OR], 4.7; 95% confidence interval [CI], 2.2-10.3) and nine times more common among "unexposed women" (OR, 9.1; 95% CI, 4.3-19.6).
  • CONCLUSION: Gastric adenocarcinoma of the intestinal type is less common in women with high endogenous estrogen exposure, indicating a preventive effect of estrogen.
  • [MeSH-major] Adenocarcinoma / pathology. Estrogen Receptor alpha / metabolism. Estrogen Receptor beta / metabolism. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18825311.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Estrogen Receptor alpha; 0 / Estrogen Receptor beta; 0 / Estrogens; 0 / Protein Isoforms
  •  go-up   go-down


25. Rendón-Huerta E, Teresa F, Teresa GM, Xochitl GS, Georgina AF, Veronica ZZ, Montaño LF: Distribution and expression pattern of claudins 6, 7, and 9 in diffuse- and intestinal-type gastric adenocarcinomas. J Gastrointest Cancer; 2010 Mar;41(1):52-9
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distribution and expression pattern of claudins 6, 7, and 9 in diffuse- and intestinal-type gastric adenocarcinomas.
  • INTRODUCTION: Intestinal- and diffuse-type gastric adenocarcinomas differ in clinical outcome and genetic profile.
  • Our aim was to find specific claudin markers for each type.
  • METHODS: Fifty paraffin-embedded tissue blocks of diffuse- and intestinal-type gastric adenocarcinomas and fresh gastric biopsies obtained endoscopically from 20 patients with a presumptive diagnosis of gastric cancer were analyzed.
  • Claudin-7 was expressed mainly in the diffuse-type whereas claudin-9 was mainly found in the apical membrane of the gland cells in the intestinal-type.
  • Strong claudin-9 expression was associated with higher mortality rate (66%) in the diffuse type vs the intestinal type (25%) after a 2-year follow-up.
  • CONCLUSION: Claudins 6, 7, and 9 expressions are closely related to gastric carcinogenesis, and their detection is a useful prognostic marker in "intestinal-" and "diffuse-type" gastric adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / metabolism. Membrane Proteins / biosynthesis. Stomach Neoplasms / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19960275.001).
  • [ISSN] 1941-6636
  • [Journal-full-title] Journal of gastrointestinal cancer
  • [ISO-abbreviation] J Gastrointest Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CLDN7 protein, human; 0 / CLDN9 protein, human; 0 / Claudins; 0 / Membrane Proteins; 0 / claudin 6
  •  go-up   go-down


26. Lee HW, Yang DH, Kim HK, Lee BH, Choi KC, Choi YH, Park YE: Expression of MUC2 in gastric carcinomas and background mucosae. J Gastroenterol Hepatol; 2007 Aug;22(8):1336-43
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND AIM: Gastric carcinomas contain elements of both intestinal and diffuse types.
  • Such heterogeneous components may distort the evaluation of the role of the mucin MUC2 in gastric carcinoma.
  • Although the expression rate of MUC2 antigens was higher in intestinal-type adenocarcinoma than in diffuse-type adenocarcinoma, a significant correlation with pathologic staging of the TNM system (pTNM staging) and MUC2 expression could not be found in each subtype of gastric carcinomas.
  • Further investigations regarding the role of MUC2 expression in gastric carcinoma and background mucosae are necessary.
  • [MeSH-major] Carcinoma / metabolism. Gastric Mucosa / metabolism. Mucins / metabolism. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17559374.001).
  • [ISSN] 0815-9319
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / MUC2 protein, human; 0 / Mucin-2; 0 / Mucins
  •  go-up   go-down


27. Wen ZS, Chen XQ, Wu HY, Wei WD, Rong TH: [Efficacy of gefitinib on advanced non-small cell lung cancer of bilateral diffuse or unilateral giant mass type]. Ai Zheng; 2007 Apr;26(4):415-7
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of gefitinib on advanced non-small cell lung cancer of bilateral diffuse or unilateral giant mass type].
  • This study was to select NSCLC patients of suitable type by comparing the efficacy of gefitinib on advanced NSCLC of bilateral diffuse type and unilateral giant mass type.
  • METHODS: Fifty advanced NSCLC patients of bilateral diffuse type (20 cases) and unilateral mass type (30 cases) received treatment of gefitinib.
  • RESULTS: The median time to symptom improvement was significantly shorter in bilateral diffuse group than in unilateral mass group (4 days vs. 7 days, P<0.01).
  • The disease control rate was significantly higher in bilateral diffuse group than in unilateral mass group (75% vs. 20%, P<0.01).
  • The median progression-free time was significantly longer in bilateral diffuse group than in unilateral mass group (9.5 months vs. 3.6 months, P<0.01).
  • CONCLUSIONS: Gefitinib is more effective to bilateral diffuse type NSCLC than to unilateral giant mass type NSCLC.
  • It can be considered as the second-line medicine for bilateral diffuse type NSCLC.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Quinazolines / therapeutic use
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adult. Aged. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Diarrhea / chemically induced. Disease-Free Survival. Exanthema / chemically induced. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Pruritus / chemically induced. Quality of Life. Remission Induction

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17430664.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] Clinical Trial; Comparative Study; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; S65743JHBS / gefitinib
  •  go-up   go-down


28. Yamashita H, Kitayama J, Shida D, Ishikawa M, Hama K, Aoki J, Arai H, Nagawa H: Differential expression of lysophosphatidic acid receptor-2 in intestinal and diffuse type gastric cancer. J Surg Oncol; 2006 Jan 1;93(1):30-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of lysophosphatidic acid receptor-2 in intestinal and diffuse type gastric cancer.
  • Recently, it was reported that malignant transformation resulted in aberrant expression of LPA2 in a various type of cancer, suggesting the positive role of LPA2 in tumor development.
  • RESULTS: LPA2 was preferentially expressed (67%) in intestinal-type cancer that was significantly higher than that in diffuse-type cancer (32%, P < 0.0001).
  • The expression of LPA2 showed correlation with a higher rate of lymphatic and venous invasion, lymphatic metastasis, and resultingly tumor stage in diffuse-type cancer, but not in intestinal-type cancer.
  • CONCLUSIONS: Our results highlight the possibility that LPA2 expression is an important process in the carcinogenesis of gastric cancer, especially in intestinal-type cancer.
  • Since LPA can transactivate HGF receptor (c-Met) as well as EGF-receptor, LPA may promote the progression of gastric cancer in diffuse-type with high expression of c-Met.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Aged. Carcinoma, Signet Ring Cell / metabolism. Carcinoma, Signet Ring Cell / pathology. Female. Gastrectomy. Humans. Immunohistochemistry. Liver Neoplasms / secondary. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness


29. Hosseini HA, Ahani A, Galehdari H, Froughmand AM, Hosseini M, Masjedizadeh A, Zali MR: Frequent loss of heterozygosity at 8p22 chromosomal region in diffuse type of gastric cancer. World J Gastroenterol; 2007 Jun 28;13(24):3354-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequent loss of heterozygosity at 8p22 chromosomal region in diffuse type of gastric cancer.
  • AIM: To study the loss of heterozygosity (LOH) at 8p21-23 locus in diffuse gastric cancer.
  • METHODS: To evaluate the involvement of this region in gastric cancer, we used eight microsatellite markers covering two Mb of mentioned region, to perform a high-resolution analysis of allele loss in 42 cases of late diffuse gastric adenocarcinoma.

  • Genetic Alliance. consumer health - Signet ring cell carcinoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17659675.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Isoenzymes; EC 2.3.1.5 / Arylamine N-Acetyltransferase; EC 2.3.1.5 / N-acetyltransferase 1; EC 2.3.1.5 / NAT2 protein, human
  • [Other-IDs] NLM/ PMC4172716
  •  go-up   go-down


30. Takashima A, Shirao K, Hirashima Y, Takahari D, Okita NT, Nakajima TE, Kato K, Hamaguchi T, Yamada Y, Shimada Y: Sequential chemotherapy with methotrexate and 5-fluorouracil for chemotherapy-naive advanced gastric cancer with disseminated intravascular coagulation at initial diagnosis. J Cancer Res Clin Oncol; 2010 Feb;136(2):243-8
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nineteen patients (86%) had histologically diffuse-type adenocarcinoma and 18 (82%) had bone metastasis.
  • [MeSH-major] Adenocarcinoma / complications. Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disseminated Intravascular Coagulation / etiology. Stomach Neoplasms / complications. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19727819.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


31. Retterspitz MF, Mönig SP, Schreckenberg S, Schneider PM, Hölscher AH, Dienes HP, Baldus SE: Expression of {beta}-catenin, MUC1 and c-met in diffuse-type gastric carcinomas: correlations with tumour progression and prognosis. Anticancer Res; 2010 Nov;30(11):4635-41
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of {beta}-catenin, MUC1 and c-met in diffuse-type gastric carcinomas: correlations with tumour progression and prognosis.
  • Therefore, a series of 94 diffuse-type and mixed-type subcardial gastric carcinomas according to the Laurén classification were investigated to elucidate possible correlations with clinico-pathological and prognostic data.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma, Mucinous / metabolism. Carcinoma, Signet Ring Cell / metabolism. Mucin-1 / metabolism. Proto-Oncogene Proteins c-met / metabolism. Stomach Neoplasms / metabolism. beta Catenin / metabolism


32. McCluggage WG, Shah R, Connolly LE, McBride HA: Intestinal-type cervical adenocarcinoma in situ and adenocarcinoma exhibit a partial enteric immunophenotype with consistent expression of CDX2. Int J Gynecol Pathol; 2008 Jan;27(1):92-100
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intestinal-type cervical adenocarcinoma in situ and adenocarcinoma exhibit a partial enteric immunophenotype with consistent expression of CDX2.
  • Most cases of cervical adenocarcinoma in situ (AIS) and adenocarcinoma are of the usual or endocervical type.
  • However, intestinal types of AIS and adenocarcinoma exist.
  • With an intestinal-type adenocarcinoma in the cervix, the question may arise as to whether one is dealing with a primary cervical neoplasm or direct or secondary spread from an intestinal adenocarcinoma.
  • In organs such as the ovary, urinary bladder, esophagus, and gallbladder, intestinal-type glandular epithelium often expresses enteric markers, but this has hardly been studied in the cervix.
  • The purpose of this study was to investigate whether intestinal-type AIS and adenocarcinoma in the cervix express enteric markers and to ascertain whether these antibodies are of value in the distinction from a metastatic intestinal adenocarcinoma.
  • We compared the immunophenotype of these lesions with that of usual-type AIS and adenocarcinomain the cervix.
  • Cases included were AIS of usual type (n = 6), primary cervical adenocarcinoma of usual type (n = 6), AIS of intestinal type (n = 21), primary cervical adenocarcinoma of intestinal type (n = 3), primary cervical adenocarcinoma with signet ring cells (n = 2), and colorectal adenocarcinoma involving the cervix (n = 5).
  • Usual-type AIS was always diffusely CK7 positive, typically diffusely CEA and p16 positive, and always CK20 negative.
  • Intestinal-type AIS was diffusely CK7 positive (all cases) and typically CK20 negative and diffusely CEA and p16 positive.
  • All but 1 case exhibited diffuse nuclear positivity with CDX2.
  • In addition, usual-type AIS adjacent to intestinal type was CDX2 positive in 13 of 21 cases.
  • The 3 cases of primary cervical intestinal-type adenocarcinoma were diffusely CK7 positive, focally or diffusely positive with CK20 and CDX2, and focally positive with CEA.
  • Intestinal types of cervical AIS and adenocarcinoma exhibit a partial enteric immunophenotype, usually with diffuse expression of CDX2 and, in some cases, staining with CK20.
  • Although there is immunophenotypic overlap, focal staining with CK20 together with diffuse CK7 and sometimes p16 positivity helps to distinguish intestinal types of cervical adenocarcinoma from involvement by a colorectal adenocarcinoma; CEA and CDX2 are of no value in this regard.
  • CDX2 positivity in usual-type AIS adjacent to intestinal type and in occasional cases of pure usual-type AIS may be a reflection of early intestinal differentiation before this is morphologically apparent.
  • Using a set of cases of AIS diagnosed in a single institution over a 7-year period (77 usual type; 13 intestinal type), intestinal type was more likely to be associated with early invasive adenocarcinoma than usual type (31% vs 17%), suggesting that intestinal differentiation may be a risk factor for invasion in premalignant cervical glandular lesions.
  • [MeSH-major] Adenocarcinoma / metabolism. Homeodomain Proteins / biosynthesis. Intestinal Neoplasms / metabolism. Uterine Cervical Neoplasms / metabolism
  • [MeSH-minor] Biomarkers, Tumor / analysis. Carcinoembryonic Antigen / biosynthesis. Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. Cyclin-Dependent Kinase Inhibitor p16 / biosynthesis. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Immunophenotyping. Keratin-20 / biosynthesis. Keratin-7 / biosynthesis

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18156982.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDX2 protein, human; 0 / Carcinoembryonic Antigen; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Homeodomain Proteins; 0 / Keratin-20; 0 / Keratin-7
  •  go-up   go-down


33. Mansor S, McCluggage WG: Cervical adenocarcinoma resembling breast lobular carcinoma: a hitherto Undescribed Variant of Primary Cervical Adenocarcinoma. Int J Gynecol Pathol; 2010 Nov;29(6):594-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cervical adenocarcinoma resembling breast lobular carcinoma: a hitherto Undescribed Variant of Primary Cervical Adenocarcinoma.
  • Most cervical adenocarcinomas are of the so-called usual or endocervical type, and consist entirely or predominantly of glandular formations.
  • We describe 3 cases of an unusual morphologic variant of cervical adenocarcinoma largely composed of bland epithelial cells, with occasional intracytoplasmic lumina, arranged in a variety of architectural patterns, including diffuse, small glandular, insular, trabecular, and Indian file arrangements.
  • The overall appearances closely resembled a breast lobular carcinoma.
  • In all cases, there was a minor superficial component of well-differentiated adenocarcinoma, suggesting that the component that resembled breast lobular carcinoma, arose from the differentiated neoplasm.
  • All cases were diffusely p16-positive, and 2 that underwent human papillomavirus testing contained high-risk oncogenic human papillomavirus, type 16 and 18 in 1 case each.
  • In all cases, there was loss of e-cadherin membranous immunoreactivity in the areas resembling breast lobular carcinoma, a similar pattern of staining to that seen in the latter neoplasm and possibly accounting for the morphologic features.
  • In reporting these cases, we highlight an unusual morphologic variant of cervical adenocarcinoma closely resembling breast lobular carcinoma and which may have an aggressive behavior.
  • [MeSH-major] Adenocarcinoma / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Breast Neoplasms / pathology. Carcinoma, Lobular / pathology. Female. Humans. Immunohistochemistry. Middle Aged

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20881849.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Hou Q, Wu YH, Grabsch H, Zhu Y, Leong SH, Ganesan K, Cross D, Tan LK, Tao J, Gopalakrishnan V, Tang BL, Kon OL, Tan P: Integrative genomics identifies RAB23 as an invasion mediator gene in diffuse-type gastric cancer. Cancer Res; 2008 Jun 15;68(12):4623-30
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Integrative genomics identifies RAB23 as an invasion mediator gene in diffuse-type gastric cancer.
  • RAB23 amplifications in primary gastric tumors were confirmed by both fluorescence in situ hybridization and genomic qPCR, and in two independent patient cohorts from Hong Kong and the United Kingdom RAB23 expression was significantly associated with diffuse-type GC (dGC) compared with intestinal-type GC (iGC).
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / secondary. Adult. Aged. Aged, 80 and over. Blotting, Western. Cell Movement. Chromosome Mapping. Chromosomes, Artificial, Bacterial. Cohort Studies. Female. Gene Amplification. Gene Dosage. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Genomics. Humans. Immunoenzyme Techniques. In Situ Hybridization, Fluorescence. Male. Middle Aged. Neoplasm Invasiveness. Oligonucleotide Array Sequence Analysis. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Small Interfering / pharmacology. Reverse Transcriptase Polymerase Chain Reaction. Tissue Array Analysis. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Signet ring cell carcinoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18559507.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / RNA, Small Interfering; EC 3.6.1.- / RAB23 protein, human; EC 3.6.1.- / rab GTP-Binding Proteins
  •  go-up   go-down


35. Mărgăritescu C, Mogoantă L, Mănescu P, Simionescu C, Pirici D, Streba L, Mercuţ D: The immunohistochemical profile of the adenocarcinoma of upper gastric pole. Rom J Morphol Embryol; 2007;48(3):215-35
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The immunohistochemical profile of the adenocarcinoma of upper gastric pole.
  • Although gastric adenocarcinoma continue to be the second continues to be the second cause of death worldwide, its incidence and mortality appear to have decreased in recent decades.
  • Adenocarcinomas with this location it seems that are a different, specific subtype of gastric carcinoma.
  • For this reason, we investigate histopathological and immunohistochemically 77 cases of upper gastric pole adenocarcinoma selected from a number of 472 gastric tumors.
  • Nevertheless, we pointed out the predominance of diffuse adenocarcinomas type according to Laurens classification, which immunohistochemically were strong positive to cytokeratins, EMA, CEA and lysozyme.
  • Moreover, investigation of some antigens likes lysozyme, p53, Ki67 and CD34 seems to be useful for prognostic estimation of carcinoma with this topography.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / metabolism. Esophagogastric Junction. Immunohistochemistry / methods. Stomach Neoplasms / diagnosis. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17914488.001).
  • [ISSN] 1220-0522
  • [Journal-full-title] Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  • [ISO-abbreviation] Rom J Morphol Embryol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD34; 0 / Carcinoembryonic Antigen; 0 / Keratin-19; 0 / Keratin-7; 0 / Ki-67 Antigen; 0 / Mucin-1; 0 / Tumor Suppressor Protein p53; 0 / Vimentin; EC 3.2.1.17 / Muramidase
  •  go-up   go-down


36. Tatemichi M, Sawa T, Gilibert I, Tazawa H, Katoh T, Ohshima H: Increased risk of intestinal type of gastric adenocarcinoma in Japanese women associated with long forms of CCTTT pentanucleotide repeat in the inducible nitric oxide synthase promoter. Cancer Lett; 2005 Jan 20;217(2):197-202
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased risk of intestinal type of gastric adenocarcinoma in Japanese women associated with long forms of CCTTT pentanucleotide repeat in the inducible nitric oxide synthase promoter.
  • Tandem repeat number polymorphism of a CCTTT pentanucleotide in the promoter region of the inducible nitric oxide synthase gene (iNOS) and a polymorphism of the interleukin-1beta (IL-1B) promoter at position -31 were analyzed in DNA samples from 181 Japanese control subjects and 158 gastric cancer patients, including 96 intestinal type and 62 diffuse type.
  • An association between the intestinal type of gastric adenocarcinoma and higher promoter activity of the iNOS gene was found in women, especially those having higher promoter activity of the IL-1B gene and without a history of smoking.
  • [MeSH-major] Adenocarcinoma / genetics. Microsatellite Repeats / genetics. Nitric Oxide Synthase / genetics. Promoter Regions, Genetic / genetics. Stomach Neoplasms / genetics
  • [MeSH-minor] Aged. DNA, Neoplasm / analysis. DNA, Neoplasm / genetics. Female. Helicobacter Infections / complications. Helicobacter Infections / genetics. Helicobacter pylori. Humans. Interleukin-1 / genetics. Japan. Male. Middle Aged. Nitric Oxide Synthase Type II. Polymorphism, Genetic. Risk Factors. Sex Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15617837.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Interleukin-1; EC 1.14.13.39 / NOS2 protein, human; EC 1.14.13.39 / Nitric Oxide Synthase; EC 1.14.13.39 / Nitric Oxide Synthase Type II
  •  go-up   go-down


37. Rabban JT, McAlhany S, Lerwill MF, Grenert JP, Zaloudek CJ: PAX2 distinguishes benign mesonephric and mullerian glandular lesions of the cervix from endocervical adenocarcinoma, including minimal deviation adenocarcinoma. Am J Surg Pathol; 2010 Feb;34(2):137-46
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PAX2 distinguishes benign mesonephric and mullerian glandular lesions of the cervix from endocervical adenocarcinoma, including minimal deviation adenocarcinoma.
  • The differential diagnosis of exuberant mesonephric hyperplasia includes minimal deviation adenocarcinoma of the cervix, a tumor with deceptively bland morphology for which no reliable diagnostic biomarkers currently exist.
  • PAX2 encodes a transcription factor necessary in the development of the Wolffian duct system, and the protein is expressed in several tumors of mesonephric origin, including renal cell carcinoma, Wilm tumor, and nephrogenic adenoma.
  • We hypothesized that PAX2 may also be expressed in mesonephric lesions of the cervix and may distinguish mesonephric hyperplasia from minimal deviation adenocarcinoma of the cervix.
  • We demonstrated that PAX2 was strongly and diffusely expressed in mesonephric remnants (6 of 6) and in mesonephric hyperplasia (18 of 18); however, no expression was noted in mesonephric adenocarcinoma (0 of 1).
  • In contrast, only 2 cases of endocervical adenocarcinoma were positive for PAX2 [invasive adenocarcinoma of the minimal deviation type (0 of 5), usual type (1 of 22), and endometrioid type (1 of 1)].
  • Adjacent adenocarcinoma in situ, as well as cases of pure adenocarcinoma in situ (0 of 6), were also PAX2 negative.
  • These results suggest that PAX2 immunoreactivity may be useful to (1) distinguish mesonephric hyperplasia from minimal deviation adenocarcinoma, (2) to distinguish lobular endocervical glandular hyperplasia from minimal deviation adenocarcinoma, and (3) to distinguish endocervical tubal metaplasia or cervical endometriosis from endocervical adenocarcinoma in situ.
  • Overall, a strong, diffuse nuclear PAX2 expression pattern in a cervical glandular proliferation predicts a benign diagnosis (positive predictive value 90%, negative predictive value 98%; P<0.001); however, PAX2 should not be interpreted in isolation from the architectural and cytologic features of the lesion as it may be expressed in some stage II endometrial adenocarcinomas involving the cervix.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenoma / diagnosis. Cervix Uteri / pathology. Mesonephros / pathology. Mullerian Ducts / pathology. PAX2 Transcription Factor / metabolism. Uterine Cervical Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20061933.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / PAX2 Transcription Factor; 0 / PAX2 protein, human
  •  go-up   go-down


38. Smith BR, Stabile BE: Extreme aggressiveness and lethality of gastric adenocarcinoma in the very young. Arch Surg; 2009 Jun;144(6):506-10
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extreme aggressiveness and lethality of gastric adenocarcinoma in the very young.
  • OBJECTIVE: To determine whether very young patients with gastric adenocarcinoma as compared with older patients with the disease have a biologically more aggressive form of the disease, presenting at an advanced stage and conferring unusually poor perioperative and long-term outcomes.
  • DESIGN, SETTING, AND PATIENTS: A 15-year, single-institution, retrospective review and analysis of demographic and outcomes data for 350 patients diagnosed with gastric adenocarcinoma.
  • Very young patients (aged < or = 35 years) as compared with older patients (aged > 35 years) more often had diffuse-type tumor histologic findings (93% vs 69%, respectively; P = .003), adjacent organ invasion (74% vs 29%, respectively; P = .001), nodal metastases (94% vs 70%, respectively; P = .046), distant metastases (81% vs 50%, respectively; P = .003), and stage IV disease (90% vs 64%, respectively; P = .007).
  • CONCLUSIONS: Very young patients (aged < or = 35 years) with gastric adenocarcinoma have significantly higher incidences of diffuse-type tumor histologic findings and both locally advanced and metastatic disease at presentation.
  • [MeSH-major] Adenocarcinoma / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19528381.001).
  • [ISSN] 1538-3644
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Kim GH, Kim KB, Lim EK, Choi SH, Kim TO, Heo J, Kang DH, Song GA, Cho M, Park DY: Analysis of endoscopic electronic image of intramucosal gastric carcinoma using a software program for calculating hemoglobin index. J Korean Med Sci; 2006 Dec;21(6):1041-7
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of endoscopic electronic image of intramucosal gastric carcinoma using a software program for calculating hemoglobin index.
  • The aims of this study were to make a software program to calculate the IHb and then to investigate whether the mucosal IHb determined from the electronic endoscopic data is a useful marker for evaluating the color of intramucosal gastric carcinoma with regard to its value for discriminating between the histologic types.
  • By using this program, the mean values of the IHb for the carcinoma (IHb-C) and those of the IHb for the surrounding non-cancerous mucosa (IHb-N) were calculated in 75 intestinal-type and 34 diffuse-type intramucosal gastric carcinomas.
  • The C/N ratio in the intestinal-type carcinoma group was higher than that in the diffuse-type carcinoma group (p<0.001).
  • In the diffuse-type carcinoma group, the C/N ratio in the body was lower than that in the antrum (p=0.022).
  • The accuracy rate, sensitivity, specificity, and the positive and negative predictive values for the differential diagnosis of the diffuse-type carcinoma from the intestinal-type carcinoma were 94.5%, 94.1%, 94.7%, 88.9% and 97.3%, respectively.
  • IHb is useful for making quantitative measurement of the endoscopic color in the intramucosal gastric carcinoma, and the C/N ratio by using the IHb would be helpful for distinguishing the diffuse-type carcinoma from the intestinal-type carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endoscopy. 1992 Jul;24 Suppl 2:522-6 [1396394.001]
  • [Cites] Br J Surg. 1992 Mar;79(3):241-4 [1313325.001]
  • [Cites] Endoscopy. 1993 Sep;25(7):445-50 [8261986.001]
  • [Cites] Endoscopy. 1997 Jun;29(5):366-71 [9270917.001]
  • [Cites] Gastrointest Endosc. 1997 Sep;46(3):212-6 [9378206.001]
  • [Cites] Endoscopy. 1997 Sep;29(7):614-9 [9360870.001]
  • [Cites] Gastrointest Endosc. 1998 Nov;48(5):470-6 [9831834.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Endoscopy. 2005 Feb;37(2):178-82 [15692936.001]
  • [Cites] Endoscopy. 2005 May;37(5):479-86 [15844029.001]
  • [Cites] Gastrointest Endosc. 2000 Aug;52(2):241-5 [10922102.001]
  • [Cites] Gastrointest Endosc. 2003 Apr;57(4):567-79 [12665775.001]
  • [Cites] Cancer. 1984 Jan 1;53(1):162-5 [6689997.001]
  • [Cites] J Surg Oncol. 1986 Nov;33(3):170-5 [3773535.001]
  • [Cites] Gastrointest Endosc. 1988 Jul-Aug;34(4):332-6 [3410246.001]
  • [Cites] Endoscopy. 1989 Jul;21(4):159-64 [2776700.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1990;417(1):29-35 [2113738.001]
  • [Cites] Dig Dis Sci. 1990 Nov;35(11):1340-4 [2226095.001]
  • [Cites] Endoscopy. 1991 Nov;23(6):321-4 [1778135.001]
  • [Cites] Cancer. 1993 Jul 1;72(1):32-6 [8508426.001]
  • (PMID = 17179684.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Hemoglobins; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ PMC2721926
  •  go-up   go-down


40. Goldman NA, Katz EB, Glenn AS, Weldon RH, Jones JG, Lynch U, Fezzari MJ, Runowicz CD, Goldberg GL, Charron MJ: GLUT1 and GLUT8 in endometrium and endometrial adenocarcinoma. Mod Pathol; 2006 Nov;19(11):1429-36
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] GLUT1 and GLUT8 in endometrium and endometrial adenocarcinoma.
  • Regulation of glucose transport facilitator expression has been demonstrated in endometrial tissue and endometrial adenocarcinoma.
  • GLUT1 and GLUT8 demonstrated diffuse intracellular localization in the cancer subtypes.
  • [MeSH-major] Adenocarcinoma / chemistry. Biomarkers, Tumor / analysis. Endometrial Neoplasms / chemistry. Endometrium / chemistry. Glucose Transport Proteins, Facilitative / analysis. Glucose Transporter Type 1 / analysis

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16892013.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK47425; United States / NHLBI NIH HHS / HL / HL58119
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glucose Transport Proteins, Facilitative; 0 / Glucose Transporter Type 1; 0 / SLC2A1 protein, human; 0 / SLC2A8 protein, human
  •  go-up   go-down


41. Saad RS, Ismiil N, Dubé V, Nofech-Mozes S, Khalifa MA: CDX-2 expression is a common event in primary intestinal-type endocervical adenocarcinoma. Am J Clin Pathol; 2009 Oct;132(4):531-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CDX-2 expression is a common event in primary intestinal-type endocervical adenocarcinoma.
  • We studied the expression of cytokeratin (CK) 7, CK20, CDX-2, and p16 in 119 cervical adenocarcinomas (65 usual type [50 invasive; 15 in situ], 37 intestinal type [21 invasive; 16 in situ], 10 endometrioid, 5 adenosquamous, and 2 signet-ring carcinomas) in comparison with 55 cases of rectal adenocarcinomas.
  • CK20 immunostaining was diffuse in the majority of rectal tumors but focal in most cervical tumors.
  • CDX-2 was expressed in all cases of rectal adenocarcinoma and in 46 cervical adenocarcinomas (38.7%): usual type, 10 (15%); intestinal type, 31 (84%); endometrioid type, 5 (50%); adenosquamous and signet-ring types, 0 (0%).
  • [MeSH-major] Adenocarcinoma / physiopathology. Homeodomain Proteins / biosynthesis. Trans-Activators / biosynthesis. Uterine Cervical Neoplasms / physiopathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19762530.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Homeodomain Proteins; 0 / Keratin-20; 0 / Keratin-7; 0 / Trans-Activators; 156560-97-3 / Cdx-2-3 protein
  •  go-up   go-down


42. Albores-Saavedra J, Simpson K, Dancer YJ, Hruban R: Intestinal type adenocarcinoma: a previously unrecognized histologic variant of ductal carcinoma of the pancreas. Ann Diagn Pathol; 2007 Feb;11(1):3-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intestinal type adenocarcinoma: a previously unrecognized histologic variant of ductal carcinoma of the pancreas.
  • These pancreatic carcinomas of intestinal type represented 10% of 110 consecutively removed ductal carcinomas of the pancreas.
  • All intestinal type carcinomas expressed cytokeratin 7, carcinoembryonic antigen, CDX2, and MUC2.
  • The pattern of reactivity of cytokeratin 7 and carcinoembryonic antigen was diffuse, whereas that of mucin 2 staining and CDX2 nuclear labeling was focal and confined predominantly to goblet cells and less frequently to columnar cells.
  • Five carcinomas were associated with high-grade pancreatic intraepithelial neoplasia of intestinal type.
  • More studies are needed to determine the biologic behavior of this distinctive histologic variant of ductal adenocarcinoma of the pancreas.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Ductal / pathology. Intestinal Neoplasms / pathology. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17240300.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDX2 protein, human; 0 / Carcinoembryonic Antigen; 0 / Homeodomain Proteins; 0 / Keratin-7; 0 / MUC2 protein, human; 0 / Mucin-2; 0 / Mucins
  •  go-up   go-down


43. Nakayama N, Koizumi W, Tanabe S, Sasaki T, Saigenji K: A phase II study of combined chemotherapy with methotrexate, 5-fluorouracil, and low-dose cisplatin (MFP) for histologically diffuse-type advanced and recurrent gastric cancer (KDOG9501). Gastric Cancer; 2006;9(3):185-91
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of combined chemotherapy with methotrexate, 5-fluorouracil, and low-dose cisplatin (MFP) for histologically diffuse-type advanced and recurrent gastric cancer (KDOG9501).
  • BACKGROUND: Histologically diffuse-type gastric cancer is well known to have a poor prognosis and is often complicated with abdominal and pleural effusions.
  • We evaluated the efficacy of a low dose of cisplatin combined with methotrexate and 5-fluorouracil (MFP therapy) in diffuse-type advanced gastric cancer.
  • CONCLUSION: MFP therapy is useful for the management of diffuse-type inoperable and recurrent gastric cancer, even in patients with conditions such as pleural effusion, ascites, or lymphangitis carcinomatosa who have a poor prognosis or cannot eat solid food.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Stomach Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Signet ring cell carcinoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16952036.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


44. Kiyono K, Suzuki HI, Morishita Y, Komuro A, Iwata C, Yashiro M, Hirakawa K, Kano MR, Miyazono K: c-Ski overexpression promotes tumor growth and angiogenesis through inhibition of transforming growth factor-beta signaling in diffuse-type gastric carcinoma. Cancer Sci; 2009 Oct;100(10):1809-16
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] c-Ski overexpression promotes tumor growth and angiogenesis through inhibition of transforming growth factor-beta signaling in diffuse-type gastric carcinoma.
  • We previously showed that disruption of TGF-beta signaling by dominant-negative TGF-beta type II receptor in a diffuse-type gastric carcinoma model accelerated tumor growth through induction of tumor angiogenesis by decreased expression of the anti-angiogenic factor thrombospondin (TSP)-1.
  • Here, we examined the function of c-Ski in human diffuse-type gastric carcinoma OCUM-2MLN cells.
  • Similar to tumors expressing dominant-negative TGF-beta type II receptor, histochemical studies revealed less fibrosis and increased angiogenesis in xenografted tumors expressing c-Ski compared to control tumors.
  • These findings suggest that c-Ski overexpression promotes the growth of diffuse-type gastric carcinoma through induction of angiogenesis.
  • [MeSH-major] Adenocarcinoma / metabolism. DNA-Binding Proteins / biosynthesis. Neovascularization, Pathologic / metabolism. Proto-Oncogene Proteins / biosynthesis. Signal Transduction / physiology. Stomach Neoplasms / metabolism. Transforming Growth Factor beta / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19594546.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Proto-Oncogene Proteins; 0 / Thrombospondin 1; 0 / Transforming Growth Factor beta; 126648-96-2 / SKI protein, human
  •  go-up   go-down


45. Guilford P, Humar B, Blair V: Hereditary diffuse gastric cancer: translation of CDH1 germline mutations into clinical practice. Gastric Cancer; 2010 Mar;13(1):1-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hereditary diffuse gastric cancer: translation of CDH1 germline mutations into clinical practice.
  • Hereditary diffuse gastric cancer (HDGC) is the only known cancer syndrome that is dominated by gastric adenocarcinoma.
  • Intestinal-type gastric cancer is not part of the syndrome.
  • [MeSH-major] Cadherins / genetics. Carcinoma, Signet Ring Cell / genetics. Germ-Line Mutation. Stomach Neoplasms / genetics


46. Dainty LA, Krivak TC, Webb JC, Zahn CM, Elkas JC, Chernofsky MR, Rose GS, Maxwell GL: Diffuse laminar endocervical glandular hyperplasia: a case report. Int J Gynecol Cancer; 2009 Aug;19(6):1091-3
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse laminar endocervical glandular hyperplasia: a case report.
  • BACKGROUND: Diffuse laminar endocervical glandular hyperplasia is extremely rare with only 14 cases reported in the literature.
  • Diffuse laminar endocervical glandular hyperplasia is a benign lesion that is easily confused with malignancy.
  • Colposcopic-directed cervical biopsies were diagnosed as adenocarcinoma, suggestive of minimal deviation adenocarcinoma.
  • Final pathology revealed diffuse laminar endocervical glandular hyperplasia.
  • CONCLUSIONS: Diffuse laminar endocervical glandular hyperplasia is an uncommon histological type of pseudoneoplastic glandular lesions that may be found in the cervix, and this entity should be considered in the differential diagnosis of a potentially malignant endocervical glandular lesion.
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Diagnosis, Differential. Female. Humans. Hyperplasia / diagnosis. Hyperplasia / pathology. Postpartum Period. Precancerous Conditions / diagnosis. Young Adult

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19820374.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Shinto O, Yashiro M, Toyokawa T, Nishii T, Kaizaki R, Matsuzaki T, Noda S, Kubo N, Tanaka H, Doi Y, Ohira M, Muguruma K, Sawada T, Hirakawa K: Phosphorylated smad2 in advanced stage gastric carcinoma. BMC Cancer; 2010;10:652
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phosphorylated smad2 in advanced stage gastric carcinoma.
  • Although Smad signal is a critical integrator of TGFβ receptor signaling transduction systems, not much is known about the role of Smad2 expression in gastric carcinoma.
  • The p-Smad2 expression level was significantly higher in diffuse type carcinoma (p = 0.007), tumours with peritoneal metastasis (p = 0.017), and tumours with lymph node metastasis (p = 0.047).
  • CONCLUSION: The expression of p-Smad2 is associated with malignant phenotype and poor prognosis in patients with advanced gastric carcinoma.
  • [MeSH-major] Adenocarcinoma / chemistry. Peritoneal Neoplasms / chemistry. Smad2 Protein / analysis. Stomach Neoplasms / chemistry

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2010 Mar 2;102(5):844-51 [20145621.001]
  • [Cites] Cancer Res. 2008 Nov 15;68(22):9107-11 [19010878.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):889-95 [11221876.001]
  • [Cites] Nat Genet. 2001 Oct;29(2):117-29 [11586292.001]
  • [Cites] Cancer Res. 2002 Jan 15;62(2):497-505 [11809701.001]
  • [Cites] Cancer Sci. 2003 Mar;94(3):230-4 [12824914.001]
  • [Cites] Cancer J. 2003 Jul-Aug;9(4):302-12 [12967141.001]
  • [Cites] Nature. 2003 Oct 9;425(6958):577-84 [14534577.001]
  • [Cites] Cancer Res. 2003 Dec 15;63(24):8848-52 [14695201.001]
  • [Cites] Int J Cancer. 1989 Sep 15;44(3):394-8 [2777404.001]
  • [Cites] Br J Cancer. 1994 Apr;69(4):777-83 [8142266.001]
  • [Cites] Br J Cancer. 1996 Oct;74(7):1096-103 [8855981.001]
  • [Cites] Cancer. 1997 Nov 1;80(9):1803-4 [9351551.001]
  • [Cites] Mod Pathol. 1998 Feb;11(2):155-68 [9504686.001]
  • [Cites] Oncology. 1998 Nov-Dec;55(6):582-7 [9778627.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Cancer Sci. 2004 Nov;95(11):893-900 [15546507.001]
  • [Cites] Cancer Sci. 2005 Jul;96(7):451-5 [16053517.001]
  • [Cites] J Cell Sci. 2005 Aug 15;118(Pt 16):3573-84 [16105881.001]
  • [Cites] Genes Dev. 2005 Dec 1;19(23):2783-810 [16322555.001]
  • [Cites] J Gastroenterol Hepatol. 2006 Feb;21(2):432-7 [16509870.001]
  • [Cites] J Surg Oncol. 2006 Jul 1;94(1):51-6 [16788944.001]
  • [Cites] Cancer Cell. 2007 Feb;11(2):147-60 [17292826.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3460-5 [17307870.001]
  • [Cites] Clin Cancer Res. 2008 May 1;14(9):2850-60 [18451253.001]
  • [Cites] Cell. 2008 Jul 25;134(2):215-30 [18662538.001]
  • [Cites] Anticancer Res. 2000 Nov-Dec;20(6B):4489-93 [11205293.001]
  • (PMID = 21110833.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / SMAD2 protein, human; 0 / Smad2 Protein
  • [Other-IDs] NLM/ PMC3001722
  •  go-up   go-down


48. Zhao L, Shen ZX, Luo HS, Shen L: Possible involvement of leptin and leptin receptor in developing gastric adenocarcinoma. World J Gastroenterol; 2005 Dec 28;11(48):7666-70
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Possible involvement of leptin and leptin receptor in developing gastric adenocarcinoma.
  • AIM: To investigate the expression of leptin and leptin receptor (ob-R) in intestinal-type gastric cancer and precancerous lesions, and to explore the possible mechanism and role of the leptin system in developing intestinal-type gastric adenocarcinoma.
  • METHODS: Immunohistochemistry was performed to examine the expression of leptin and leptin receptor in archival samples of gastric adenocarcinoma and preneoplastic lesions, including intestinal metaplasia and mild to severe gastric epithelial dysplasia.
  • RESULTS: Dual expression of leptin and leptin receptor were detected in 80% (16/20) intestinal metaplasia, 86.3% (25/30) mild gastric epithelial dysplasia, 86.7% (26/30) moderate gastric epithelial dysplasia, 93.3% (28/30) severe gastric epithelial dysplasia, 91.3% (55/60) intestinal-type gastric adenocarcinoma and 30.0% (9/30) diffuse-type gastric carcinoma.
  • The percentage of dual expression of leptin and leptin receptor in intestinal-type gastric adenocarcinoma was significantly higher than that in diffuse-type gastric adenocarcinoma (c2 = 37.022, P<0.01).
  • CONCLUSION: Our results indicate the presence of an autocrine loop of leptin system in the development of intestinal-type gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / etiology. Leptin / physiology. Receptors, Cell Surface / physiology. Stomach Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16437696.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Leptin; 0 / Receptors, Cell Surface; 0 / Receptors, Leptin; 0 / leptin receptor, human; EC 2.7.1.- / Phosphatidylinositol 3-Kinases
  • [Other-IDs] NLM/ PMC4727216
  •  go-up   go-down


49. Chin K, Fujimura M, Sekit N, Mikami K, Kamijima S, Suzuki H, Ichikawa T: [Case of malignant lymphoma of the prostate complicated with prostate adenocarcinoma]. Nihon Hinyokika Gakkai Zasshi; 2009 Nov;100(7):698-702
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Case of malignant lymphoma of the prostate complicated with prostate adenocarcinoma].
  • Esophagogastroduodenoscopy revealed a huge ulcer in the stomach, and based on biopsy findings, he was pathologically diagnosed as having diffuse large B-cell type malignant lymphoma.
  • Histological findings revealed diffuse large B-cell type malignant lymphoma and moderately differentiated adenocarcinoma of the prostate.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Large B-Cell, Diffuse / drug therapy. Neoplasms, Multiple Primary. Prostatic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19999135.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  • [Number-of-references] 12
  •  go-up   go-down


50. Kim SM, Cho SJ, Jang WY, Kim DH, Shin HS, Jang MK, Kim HY, Nam ES: Expression of maspin is associated with the intestinal type of gastric adenocarcinoma. Cancer Res Treat; 2005 Aug;37(4):228-32

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of maspin is associated with the intestinal type of gastric adenocarcinoma.
  • In addition, the intestinal type of tumors showed significantly higher expression levels compared to the diffuse type of tumors (81.5% vs. 48.6%, p<0.05).
  • CONCLUSION: Our results suggest that Maspin is frequently expressed in human gastric cancers, and its expression might be associated with tumorigenesis of the intestinal type of gastric cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell Growth Differ. 1997 Feb;8(2):179-86 [9040939.001]
  • [Cites] World J Gastroenterol. 2003 Jan;9(1):40-3 [12508348.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3147-51 [7724531.001]
  • [Cites] J Biol Chem. 1994 Dec 9;269(49):30988-93 [7983035.001]
  • [Cites] Science. 1994 Jan 28;263(5146):526-9 [8290962.001]
  • [Cites] Cancer Res. 1992 Dec 15;52(24):6735-40 [1458460.001]
  • [Cites] J Invest Dermatol. 2004 Mar;122(3):805-11 [15086568.001]
  • [Cites] Korean J Intern Med. 2004 Mar;19(1):15-8 [15053038.001]
  • [Cites] World J Gastroenterol. 2004 Mar 1;10(5):634-7 [14991928.001]
  • [Cites] Oncogene. 2004 Feb 5;23(5):1117-24 [14743202.001]
  • [Cites] Dig Dis Sci. 2002 Aug;47(8):1831-5 [12184537.001]
  • [Cites] Int J Cancer. 2002 Aug 1;100(4):452-5 [12115529.001]
  • [Cites] Nat Genet. 2002 Jun;31(2):175-9 [12021783.001]
  • [Cites] World J Gastroenterol. 2001 Feb;7(1):53-9 [11819733.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):812-7 [11309327.001]
  • [Cites] Br J Cancer. 2005 Mar 28;92(6):1130-6 [15770218.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7740-7 [15520178.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jan 20;95(2):499-504 [9435220.001]
  • [Cites] Am J Pathol. 2003 Nov;163(5):1911-9 [14578190.001]
  • [Cites] Pathol Int. 2002 Aug;52(8):508-13 [12366809.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11669-74 [8876194.001]
  • [Cites] Histopathology. 2003 Jun;42(6):541-5 [12786889.001]
  • [Cites] Clin Cancer Res. 2002 Sep;8(9):2924-32 [12231537.001]
  • (PMID = 19956519.001).
  • [ISSN] 2005-9256
  • [Journal-full-title] Cancer research and treatment : official journal of Korean Cancer Association
  • [ISO-abbreviation] Cancer Res Treat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2785921
  • [Keywords] NOTNLM ; Gastric adenocarcinoma / Immunohistochemistry / Maspin / Nested RT-PCR
  •  go-up   go-down


51. Yamashita H, Kitayama J, Ishikawa M, Nagawa H: Tissue factor expression is a clinical indicator of lymphatic metastasis and poor prognosis in gastric cancer with intestinal phenotype. J Surg Oncol; 2007 Mar 15;95(4):324-31
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: TF was preferentially expressed (41.8%) in intestinal-type cancer at a significantly higher rate than that in diffuse-type cancer (12.1%, P<0.0001).
  • The expression of TF was associated with advanced stage of disease and showed a positive correlation with a higher rate of lymphatic and venous invasion and lymphatic metastasis in intestinal-type, but not in diffuse-type carcinoma.
  • Moreover, TF expression was associated with high MVD in the tumor and a worse outcome only in intestinal-type carcinoma.
  • CONCLUSIONS: TF may be critically involved in tumor progression in intestinal-type, but not in diffuse-type, gastric carcinoma.
  • [MeSH-major] Adenocarcinoma / secondary. Carcinoma, Signet Ring Cell / secondary. Intestinal Neoplasms / pathology. Lymph Nodes / pathology. Stomach Neoplasms / pathology. Thromboplastin / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc.
  • (PMID = 17066404.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 9035-58-9 / Thromboplastin
  •  go-up   go-down


52. Chandanos E, Lindblad M, Rubio CA, Jia C, Warner M, Gustafsson JA, Lagergren J: Tamoxifen exposure in relation to gastric adenocarcinoma development. Eur J Cancer; 2008 May;44(7):1007-14
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tamoxifen exposure in relation to gastric adenocarcinoma development.
  • Epidemiological research has indicated that the anti-oestrogen tamoxifen, used in breast cancer therapy, may increase the risk of gastric adenocarcinoma of the intestinal but not of the diffuse type.
  • Tumour material was reviewed histologically to verify gastric adenocarcinoma diagnosis and classify these cancers into intestinal or diffuse type.
  • Amongst 68 women with verified gastric adenocarcinoma, 30 had been treated with tamoxifen and 38 not.
  • The intestinal type of gastric adenocarcinoma was not more frequent amongst tamoxifen users (27%) than amongst non-users (34%) (p=0.601).
  • There were no material differences between the tamoxifen groups regarding distribution of any of the three ERs of the intestinal adenocarcinoma specimens.
  • Tamoxifen users had a shorter latency between breast cancer and gastric adenocarcinoma (4 versus 13 years) which was similar in the intestinal and diffuse types.
  • This study does not support the hypothesis that tamoxifen increases the isolated risk of the intestinal type, but it indicates that tamoxifen use might accelerate the tumour progression or increase the overall risk of gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / chemically induced. Antineoplastic Agents, Hormonal / adverse effects. Breast Neoplasms / drug therapy. Stomach Neoplasms / chemically induced. Tamoxifen / adverse effects

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18394879.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Biomarkers, Tumor; 0 / Receptors, Estrogen; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


53. Szachnowicz S, Cecconello I, Iriya K, Marson AG, Takeda FR, Gama-Rodrigues JJ: Origin of adenocarcinoma in Barrett's esophagus: p53 and Ki67 expression and histopathologic background. Clinics (Sao Paulo); 2005 Apr;60(2):103-12
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Origin of adenocarcinoma in Barrett's esophagus: p53 and Ki67 expression and histopathologic background.
  • Intestinal metaplasia in Barrett's esophagus is considered to be the main risk factor for the development of adenocarcinoma.
  • Diffuse adenocarcinoma and Barrett's esophagus without intestinal metaplasia are rare, and reports on the subject are scarce.
  • PURPOSE AND METHOD: To estimate the prevalence of adenocarcinoma in 297 patients with Barrett's esophagus, during the period of 1990 to 2002, and in 13 patients undergoing surgery, to conduct detailed macroscopic and microscopic analysis, with performance of immunohistochemical tests for p53 and Ki67, correlating the type of tumor with its adjacent epithelium.
  • RESULTS: In our patients with Barrett's esophagus, there was a prevalence of 5.7% of adenocarcinoma.
  • Tumors were classified according to Nakamura's classification (23% differentiated pattern, and 77% undifferentiated pattern) and to Lauren's classification (61% intestinal and 39% diffuse).
  • The difference is due to the migration of microtubular and foveolar tumors of undifferentiated (gastric) pattern in Nakamuras classification to the Lauren's intestinal type.
  • CONCLUSION: Adenocarcinoma develops from mixed columnar epithelium, either intestinal or gastric, showing both the gastric and the intestinal patterns; thus, tumors can also grow in columnar epithelium without intestinal metaplasia.
  • [MeSH-major] Adenocarcinoma / pathology. Barrett Esophagus / pathology. Esophageal Neoplasms / pathology. Ki-67 Antigen / analysis. Tumor Suppressor Protein p53 / analysis

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15880245.001).
  • [ISSN] 1807-5932
  • [Journal-full-title] Clinics (São Paulo, Brazil)
  • [ISO-abbreviation] Clinics (Sao Paulo)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


54. Koriyama C, Akiba S, Shimaoka S, Itoh T, Akiyama S, Eizuru Y: Frequent expression of thymidine phosphorylase in Epstein-Barr virus-associated gastric carcinoma of diffuse type. Anticancer Res; 2010 Jun;30(6):2431-7
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequent expression of thymidine phosphorylase in Epstein-Barr virus-associated gastric carcinoma of diffuse type.
  • PATIENTS AND METHODS: TP expression was examined by immunohistochemistry assay among 156 gastric carcinoma cases (21 EBV-GC cases and 135 non EBV-GC cases).
  • However, such an association was only observed in Lauren's diffuse-type tumors.
  • CONCLUSION: Our finding suggests that the mechanism involved in TP expression of gastric carcinoma appears to be different in intestinal- and diffuse-type tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20651404.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / RNA, Viral; 0 / Tumor Necrosis Factor-alpha; 82115-62-6 / Interferon-gamma; EC 2.4.2.4 / Thymidine Phosphorylase
  •  go-up   go-down


55. Carter JE, Nelson JJ, Eves M, Boudreaux C: Diagnosis of linitis plastica-type gastric adenocarcinoma by endoscopic ultrasound-guided fine needle aspiration: a case report. Acta Cytol; 2008 Nov-Dec;52(6):725-8
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis of linitis plastica-type gastric adenocarcinoma by endoscopic ultrasound-guided fine needle aspiration: a case report.
  • BACKGROUND: The diagnosis of linitis plastica-type adenocarcinomas of the stomach has traditionally been made by brush cytology and mucosal biopsy.
  • Computed tomography of her abdomen revealed diffuse thickening of a portion of the gastric wall.
  • Subsequent endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) of the stomach yielded abundant single, discohesive malignant cells suspicious for lymphoma vs. poorly differentiated carcinoma.
  • Special stains and immunohistochemical stains confirmed the diagnosis of poorly differentiated adenocarcinoma ofsignet ring cell type.
  • CONCLUSION: As many linitisplastica-type adenocarcinomas are submucosal lesions, mucosal sampling by biopsy may yield nondiagnostic material in up to one third of cases.
  • [MeSH-major] Adenocarcinoma / pathology. Linitis Plastica / pathology. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19068680.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Houghton O, Jamison J, Wilson R, Carson J, McCluggage WG: p16 Immunoreactivity in unusual types of cervical adenocarcinoma does not reflect human papillomavirus infection. Histopathology; 2010 Sep;57(3):342-50
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p16 Immunoreactivity in unusual types of cervical adenocarcinoma does not reflect human papillomavirus infection.
  • AIMS: The association between human papillomavirus (HPV) and cervical carcinoma is well known, with HPV being identifiable in almost all cervical squamous carcinomas and most adenocarcinomas.
  • However, the prevalence of HPV in unusual morphological types of cervical adenocarcinoma has not been investigated extensively.
  • The relationship between HPV and p16 immunoreactivity in these neoplasms was also investigated, as it is generally assumed that in cervical neoplasms diffuse p16 expression is predictive of the presence of high-risk HPV.
  • METHODS AND RESULTS: Sixty-three cervical adenocarcinomas, comprising those of usual type (n = 43), minimal deviation type (n = 4), gastric type (n = 3), intestinal type (n = 3), mesonephric type (n = 3), clear cell type (n = 4), serous type (n = 2) and hepatoid type (n = 1) underwent linear array HPV genotyping and immunohistochemistry for p16.
  • Seventy-eight per cent of usual-type adenocarcinomas were HPV-positive, as was the single serous carcinoma in which there was sufficient DNA for analysis.
  • In contrast, all minimal deviation adenocarcinomas and those of gastric, intestinal, mesonephric and clear cell types were HPV-negative, as was the single hepatoid carcinoma.
  • All usual-type adenocarcinomas exhibited p16 immunoreactivity (diffuse staining in all but one case), as did 11 of 20 of those of unusual morphological type (five focal, six diffuse).
  • CONCLUSIONS: Most, but not all, cervical adenocarcinomas of usual type contain HPV, but those of unusual morphological type are almost always HPV-negative.
  • This has implications for the efficacy of HPV vaccination in the prevention of cervical adenocarcinoma.
  • A significant proportion of cervical adenocarcinomas are p16-positive in the absence of HPV, illustrating that in these neoplasms diffuse p16 immunoreactivity is not a reliable surrogate marker of the presence of high-risk HPV.
  • [MeSH-major] Adenocarcinoma / virology. Biomarkers, Tumor / metabolism. Neoplasm Proteins / metabolism. Papillomavirus Infections / complications. Uterine Cervical Neoplasms / virology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Blackwell Publishing Limited.
  • (PMID = 20727021.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Viral; 0 / Neoplasm Proteins; 0 / P16 protein, human
  •  go-up   go-down


57. Kuroda N, Tanida N, Ohara M, Hirouchi T, Mizuno K, Kubo A, Lee GH: Anal canal adenocarcinoma with MUC5AC expression suggestive of anal gland origin. Med Mol Morphol; 2007 Mar;40(1):50-3
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal canal adenocarcinoma with MUC5AC expression suggestive of anal gland origin.
  • Microscopically, the proliferation of adenocarcinoma cells with mucin production was observed in the submucosal and muscular layers.
  • Immunohistochemically, normal rectal-type mucosa and normal anal ducts/glands showed the patterns of cytokeratin 7 (CK7)(-)/CK19(+, focal)/MUC5AC(-) and CK7(+, diffuse)/CK19(+, diffuse)/MUC5AC(+, focal), respectively, and neoplastic cells showed the pattern of CK7(+, diffuse)/CK19(+, diffuse)/MUC5AC(+, focal).
  • Finally, our preliminary report suggests that the immunohistochemical combination of CK7, CK19, and MUC5AC may be an available marker for adenocarcinoma of anal ducts/glands origin.
  • [MeSH-major] Adenocarcinoma / pathology. Anal Canal / pathology. Anus Neoplasms / pathology. Mucins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17384991.001).
  • [ISSN] 1860-1480
  • [Journal-full-title] Medical molecular morphology
  • [ISO-abbreviation] Med Mol Morphol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / MUC5AC protein, human; 0 / Mucin 5AC; 0 / Mucins
  •  go-up   go-down


58. Lee WA: Alpha-methylacyl-CoA-racemase expression in adenocarcinoma, dysplasia and non-neoplastic epithelium of the stomach. Oncology; 2006;71(3-4):246-50
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alpha-methylacyl-CoA-racemase expression in adenocarcinoma, dysplasia and non-neoplastic epithelium of the stomach.
  • This study aims to examine the expression pattern, as well as diagnostic and prognostic significance, of AMACR in carcinoma, dysplasia and non-neoplastic epithelium of the stomach.
  • A total of 158 cases, including 66 cases of gastric carcinoma (GC), 48 cases of dysplasia and 44 cases of non-neoplastic gastric mucosa, were examined by immunohistochemistry for AMACR.
  • A significantly high frequency of AMACR expression was found in 40 of 48 (83.3%) cases of dysplasia and 34 of 66 (51.5%) carcinoma cases compared with cases of non-neoplastic epithelium (p < 0.05).
  • The frequency of AMACR expression was significantly higher in dysplasia than in carcinoma cases (p < 0.05).
  • AMACR expression was higher in intestinal- than diffuse-type GC (p < 0.05).
  • It also suggests that AMACR expression is more likely to be associated with intestinal-type adenocarcinoma in gastric carcinogenesis.
  • [MeSH-major] Adenocarcinoma / enzymology. Biomarkers, Tumor / metabolism. Gastric Mucosa / enzymology. Precancerous Conditions / enzymology. Racemases and Epimerases / metabolism. Stomach Neoplasms / enzymology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17652945.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


59. Epplein M, Nomura AM, Wilkens LR, Henderson BE, Kolonel LN: Nonsteroidal antiinflammatory drugs and risk of gastric adenocarcinoma: the multiethnic cohort study. Am J Epidemiol; 2009 Aug 15;170(4):507-14
Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nonsteroidal antiinflammatory drugs and risk of gastric adenocarcinoma: the multiethnic cohort study.
  • The inverse association with regular aspirin use was observed only for intestinal-type distal gastric adenocarcinoma (HR = 0.66, 95% CI: 0.47, 0.95; P(trend) = 0.01), as opposed to diffuse-type distal gastric adenocarcinoma (HR = 0.92, 95% CI: 0.53, 1.60; P(trend) = 0.45).
  • In this study, the authors found aspirin use to be inversely associated with distal gastric adenocarcinoma, particularly of the intestinal type.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2000 Feb;6(2):519-25 [10690533.001]
  • [Cites] Br J Cancer. 2009 Feb 10;100(3):551-7 [19156150.001]
  • [Cites] Br J Cancer. 2000 Jul;83(1):127-32 [10883680.001]
  • [Cites] Epidemiol Rev. 2000;22(2):283-97 [11218379.001]
  • [Cites] Br J Cancer. 2001 Apr 6;84(7):965-8 [11286478.001]
  • [Cites] J Natl Cancer Inst. 2002 Feb 20;94(4):252-66 [11854387.001]
  • [Cites] N Engl J Med. 2002 Oct 10;347(15):1175-86 [12374879.001]
  • [Cites] Surg Oncol Clin N Am. 2002 Apr;11(2):235-56 [12424848.001]
  • [Cites] Curr Pharm Des. 2003;9(27):2281-8 [14529406.001]
  • [Cites] J Natl Cancer Inst. 2003 Dec 3;95(23):1784-91 [14652240.001]
  • [Cites] BMC Cancer. 2003 Oct 31;3:28 [14588079.001]
  • [Cites] Cancer Res. 1997 Apr 1;57(7):1276-80 [9102213.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Feb;7(2):97-102 [9488582.001]
  • [Cites] Int J Cancer. 1999 Aug 12;82(4):473-6 [10404057.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):444-50 [15734971.001]
  • [Cites] J Infect Dis. 2005 Jun 15;191(12):2075-81 [15897993.001]
  • [Cites] Int J Cancer. 2006 Jul 1;119(1):202-7 [16450404.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4975-82 [16651456.001]
  • [Cites] World J Gastroenterol. 2006 May 14;12(18):2884-9 [16718813.001]
  • [Cites] Clin Cancer Res. 2006 Aug 1;12(15):4766-72 [16899628.001]
  • [Cites] Digestion. 2006;74(2):109-15 [17167266.001]
  • [Cites] Ann Intern Med. 2007 Mar 6;146(5):365-75 [17339622.001]
  • [Cites] Ann Intern Med. 2007 Mar 6;146(5):376-89 [17339623.001]
  • [Cites] Lancet. 2007 May 12;369(9573):1603-13 [17499602.001]
  • [Cites] Clin Gastroenterol Hepatol. 2007 Oct;5(10):1154-1159.e3 [17644046.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Jan;17(1):126-34 [18187391.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 May;17(5):1169-78 [18483339.001]
  • [Cites] Am J Epidemiol. 2000 Feb 15;151(4):346-57 [10695593.001]
  • (PMID = 19584132.001).
  • [ISSN] 1476-6256
  • [Journal-full-title] American journal of epidemiology
  • [ISO-abbreviation] Am. J. Epidemiol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R25 CA090956; United States / NCI NIH HHS / CA / R25 CA 90956; United States / NCI NIH HHS / CA / P01 CA33619; United States / NCI NIH HHS / CA / P01 CA033619; United States / NCI NIH HHS / CA / R25 CA90956
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; R16CO5Y76E / Aspirin
  • [Other-IDs] NLM/ PMC2727180
  •  go-up   go-down


60. Sarbia M: The histological appearance of oesophageal adenocarcinoma--an analysis based on 215 resection specimens. Virchows Arch; 2006 May;448(5):532-8
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The histological appearance of oesophageal adenocarcinoma--an analysis based on 215 resection specimens.
  • The current study was performed to determine whether the histopathological appearance of oesophageal adenocarcinoma (AC) differs significantly from that of cardiac or gastric AC.
  • According to Lauren's classification, oesophageal AC (1.4%) less frequently belonged to the diffuse type than cardiac (2.8%) and gastric AC (23.9%; p<0.0001).
  • [MeSH-major] Adenocarcinoma / classification. Adenocarcinoma / pathology. Esophageal Neoplasms / classification. Esophageal Neoplasms / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16498532.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


61. Leal M, Lima E, Silva P, Assumpção P, Calcagno D, Payão S, Burbano RR, Smith M: Promoter hypermethylation of CDH1, FHIT, MTAP and PLAGL1 in gastric adenocarcinoma in individuals from Northern Brazil. World J Gastroenterol; 2007 May 14;13(18):2568-74
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Promoter hypermethylation of CDH1, FHIT, MTAP and PLAGL1 in gastric adenocarcinoma in individuals from Northern Brazil.
  • METHODS: Methylation-specific PCR (MSP) assay was performed in 13 nonneoplastic gastric adenocarcinoma, 30 intestinal-type gastric adenocarcinoma and 35 diffuse-type gastric adenocarcinoma samples from individuals in Northern Brazil.
  • Hypermethylation of three or four genes revealed a significant association with diffuse-type gastric cancer compared with nonneoplastic cancer.
  • A higher hypermethylation frequency was significantly associated with H pylori infection in gastric cancers, especially with diffuse-type.
  • MTAP hypermethylation was associated with H pylori in gastric cancer samples, as well as with diffuse-type compared with intestinal-type.
  • In diffuse-type, MTAP hypermethylation was associated with female gender.
  • MTAP promoter hypermethylation can be characterized as a marker of diffuse-type gastric cancer, especially in women and may help in diagnosis, prognosis and therapies.
  • This infection may be correlated with the carcinogenic process through the gene promoter hypermethylation, especially the MTAP promoter in diffuse-type.
  • A higher H pylori infection in diffuse-type may be due to greater genetic predisposition.
  • [MeSH-major] Adenocarcinoma / genetics. DNA Methylation. Proteins / genetics. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2003 Dec 12;278(50):49868-73 [14506228.001]
  • [Cites] Am J Pathol. 2004 Feb;164(2):689-99 [14742272.001]
  • [Cites] Biochim Biophys Acta. 2004 Nov 5;1690(3):276-84 [15511635.001]
  • [Cites] Cancer Res. 1991 Mar 1;51(5):1448-51 [1997184.001]
  • [Cites] Biochim Biophys Acta. 1994 May 27;1198(1):11-26 [8199193.001]
  • [Cites] Cell. 1996 Feb 23;84(4):587-97 [8598045.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] J Exp Med. 1999 Dec 6;190(11):1595-604 [10587350.001]
  • [Cites] Nature. 2000 Mar 23;404(6776):398-402 [10746728.001]
  • [Cites] N Engl J Med. 2001 Jun 21;344(25):1904-9 [11419427.001]
  • [Cites] Cancer. 2001 Jun 15;91(12):2294-301 [11413518.001]
  • [Cites] Genes Dev. 2002 Jan 1;16(1):6-21 [11782440.001]
  • [Cites] Arq Gastroenterol. 2001 Oct-Dec;38(4):240-6 [12068534.001]
  • [Cites] Oncogene. 2002 Aug 12;21(35):5427-40 [12154405.001]
  • [Cites] Am J Pathol. 2002 Aug;161(2):399-403 [12163364.001]
  • [Cites] Bioinformatics. 2002 Nov;18(11):1427-31 [12424112.001]
  • [Cites] Cancer Biol Ther. 2002 May-Jun;1(3):232-6 [12432269.001]
  • [Cites] Mol Cell Biol. 2003 Feb;23(3):988-1003 [12529403.001]
  • [Cites] Gut. 2003 Apr;52(4):502-6 [12631658.001]
  • [Cites] Gastroenterology. 2003 May;124(5):1193-201 [12730860.001]
  • [Cites] Yi Chuan Xue Bao. 2003 Feb;30(2):103-8 [12776596.001]
  • [Cites] Am J Pathol. 2003 Aug;163(2):683-90 [12875987.001]
  • [Cites] Nat Rev Cancer. 2003 Aug;3(8):592-600 [12894247.001]
  • [Cites] Cancer Res. 1996 Dec 15;56(24):5653-8 [8971171.001]
  • [Cites] EMBO J. 1997 May 15;16(10):2814-25 [9184226.001]
  • [Cites] Cancer Res. 1998 Aug 1;58(15):3429-34 [9699676.001]
  • [Cites] J Biol Chem. 1998 Sep 4;273(36):23026-32 [9722527.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5032-7 [9823304.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Cancer Sci. 2004 Dec;95(12):962-8 [15596045.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Int J Oncol. 2005 Jun;26(6):1493-500 [15870861.001]
  • [Cites] World J Gastroenterol. 2005 Sep 7;11(33):5174-9 [16127748.001]
  • [Cites] Rev Med Chil. 2005 Aug;133(8):874-80 [16163424.001]
  • [Cites] Neoplasia. 2005 Aug;7(8):748-60 [16207477.001]
  • [Cites] Carcinogenesis. 2006 Jan;27(1):64-72 [16081515.001]
  • [Cites] Cancer Sci. 2006 Jan;97(1):64-71 [16367923.001]
  • [Cites] World J Gastroenterol. 2006 Jan 14;12(2):199-203 [16482618.001]
  • [Cites] Cancer. 2006 Mar 15;106(6):1250-9 [16475210.001]
  • [Cites] Diagn Mol Pathol. 2006 Mar;15(1):24-9 [16531765.001]
  • [Cites] Arch Dermatol. 2006 Apr;142(4):471-6 [16618867.001]
  • [Cites] Clin Cancer Res. 2006 May 15;12(10):3216-21 [16707623.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2006;20(4):651-74 [16997151.001]
  • [Cites] J Cell Physiol. 2007 Jan;210(1):16-25 [17063461.001]
  • (PMID = 17552003.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CDH1 protein, human; 0 / Cadherins; 0 / Cell Cycle Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / PLAGL1 protein, human; 0 / Proteins; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 0 / fragile histidine triad protein; EC 3.6.- / Acid Anhydride Hydrolases
  • [Other-IDs] NLM/ PMC4146816
  •  go-up   go-down


62. Cai JC, Liu D, Zhang HP, Zhong S, Xia NS: [Promoter methylation of several tumor suppressor genes in human gastric adenocarcinoma]. Zhonghua Yi Xue Za Zhi; 2007 Apr 10;87(14):978-81
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Promoter methylation of several tumor suppressor genes in human gastric adenocarcinoma].
  • OBJECTIVE: To study the promoter methylation of several tumor suppressor genes in human gastric foveolar epithelia (GFE) of chronic gastritis, adjacent GFE of gastric adenocarcinoma (GAC) and GAC.
  • The promote methylation rate of tumor suppressor genes in the GAC Laurén diffuse type was 80.6% (50/62), significantly higher than that of the GAC of intestinal type (61.4%, 27/44, P < 0.01).
  • [MeSH-major] Adenocarcinoma / genetics. DNA Methylation. Genes, Tumor Suppressor. Promoter Regions, Genetic. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17650424.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Adenomatous Polyposis Coli Protein; 0 / Cadherins; 0 / MLH1 protein, human; 0 / Nuclear Proteins; 0 / Tumor Suppressor Proteins; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes
  •  go-up   go-down


63. Hara S, Kijima H, Okada K, Igarashi Y: Invasive micropapillary variant of the gallbladder adenocarcinoma and its aggressive potential for lymph node metastasis. Biomed Res; 2010 Apr;31(2):89-95
MedlinePlus Health Information. consumer health - Gallbladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive micropapillary variant of the gallbladder adenocarcinoma and its aggressive potential for lymph node metastasis.
  • We analyzed the clinicopathologic findings of IMPV and compared them with those of a conventional adenocarcinoma in the gallbladder to clarify the highly aggressive potential of IMPV of gallbladder carcinoma.
  • Ninety consecutive cases of surgically resected gallbladder carcinomas were studied for age, gender, type, depth of invasion and lymph node and distant metastases.
  • Histologically, IMPV of gallbladder carcinoma was characterized by a small cluster of tumor cells lying within clear stromal spaces.
  • Of those 20 cases, 17 (85.0%) carcinomas with IMPV also included lymph node metastasis, which was more frequent than in conventional carcinoma (32.8%, P < 0.001).
  • IMPV is a useful predictor of regional lymph node metastasis in gallbladder adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma / pathology. Gallbladder Neoplasms / pathology. Lymph Nodes / pathology
  • [MeSH-minor] Humans. Lymphatic Metastasis / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Multivariate Analysis. Neoplasm Staging. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20460736.001).
  • [ISSN] 1880-313X
  • [Journal-full-title] Biomedical research (Tokyo, Japan)
  • [ISO-abbreviation] Biomed. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


64. Khayat AS, Lobo Gatti L, Moura Lima E, de Assumpção PP, Nascimento Motta FJ, Harada ML, Casartelli C, Marques Payão SL, Cardoso Smith MA, Burbano RR: Polymorphisms of the TP53 codon 72 and WRN codon 1367 in individuals from Northern Brazil with gastric adenocarcinoma. Clin Exp Med; 2005 Dec;5(4):161-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphisms of the TP53 codon 72 and WRN codon 1367 in individuals from Northern Brazil with gastric adenocarcinoma.
  • Gastric cancer is the second most frequent type of neoplasia and also the second most common cause of death in the world.
  • In the present study, the TP53 codon 72 and the WRN codon 1367 polymorphisms were investigated in 54 gastric adenocarcinoma patients (31 diffuse-type and 25 intestinal-type) and 54 controls.
  • [MeSH-major] Adenocarcinoma / genetics. Codon. DNA Helicases / genetics. Genes, p53. Polymorphism, Genetic. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16362795.001).
  • [ISSN] 1591-8890
  • [Journal-full-title] Clinical and experimental medicine
  • [ISO-abbreviation] Clin. Exp. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Codon; 0 / DNA Primers; EC 3.1.- / Exodeoxyribonucleases; EC 3.6.1.- / WRN protein, human; EC 3.6.4.- / DNA Helicases; EC 3.6.4.12 / RecQ Helicases
  •  go-up   go-down


65. Humar B, Guilford P: Hereditary diffuse gastric cancer: a manifestation of lost cell polarity. Cancer Sci; 2009 Jul;100(7):1151-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hereditary diffuse gastric cancer: a manifestation of lost cell polarity.
  • Hereditary diffuse gastric cancer is a cancer syndrome caused by germline mutations in the gene for the cell adhesion protein E-cadherin (CDH1).
  • Hereditary diffuse gastric cancer is dominated by diffuse-type gastric adenocarcinoma, often with signet ring cell morphology.
  • These same features are observed in more advanced stages of hereditary diffuse gastric cancer progression, suggesting that an epithelial-mesenchymal transition is required for tumor invasion beyond the muscularis mucosae.
  • Hereditary diffuse gastric cancer initiation requires somatic down-regulation of the second CDH1 allele, which in most cases is caused by DNA promoter hypermethylation.
  • [MeSH-minor] Animals. Carcinoma, Signet Ring Cell / genetics. Carcinoma, Signet Ring Cell / pathology. Gastric Mucosa / pathology. Germ-Line Mutation. Humans. Loss of Heterozygosity. Models, Biological


66. Toki F, Takahashi A, Aihara R, Ogata K, Ando H, Ohno T, Mochiki E, Kuwano H: Relationship between clinicopathological features and mucin phenotypes of advanced gastric adenocarcinoma. World J Gastroenterol; 2010 Jun 14;16(22):2764-70
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship between clinicopathological features and mucin phenotypes of advanced gastric adenocarcinoma.
  • AIM: To investigate a relationship between the clinicopathological features and mucin phenotypes in advanced gastric adenocarcinoma (AGA).
  • METHODS: Immunohistochemical staining was performed to determine the mucin phenotypes in 38 patients with differentiated adenocarcinomas (DACs), 9 with signet-ring cell carcinomas (SIGs), and 48 with other diffuse-type adenocarcinomas (non-SIGs) of AGA.
  • [MeSH-major] Adenocarcinoma. Carcinoma, Signet Ring Cell. Mucins / metabolism. Protein Isoforms / metabolism. Stomach Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2000 Aug 15;89(4):724-32 [10951333.001]
  • [Cites] World J Gastroenterol. 2007 Jun 21;13(23):3189-98 [17589897.001]
  • [Cites] Pathol Int. 2001 Mar;51(3):165-71 [11328531.001]
  • [Cites] Oncology. 2001;61(3):212-20 [11574777.001]
  • [Cites] Virchows Arch. 2002 Mar;440(3):304-10 [11889602.001]
  • [Cites] Hum Pathol. 2003 Jan;34(1):32-40 [12605364.001]
  • [Cites] J Cancer Res Clin Oncol. 2003 Dec;129(12):727-34 [14557879.001]
  • [Cites] Pathol Int. 2004 May;54(5):311-21 [15086835.001]
  • [Cites] Br J Cancer. 2004 Oct 4;91(7):1342-8 [15354218.001]
  • [Cites] Gan. 1968 Jun;59(3):251-8 [5726267.001]
  • [Cites] Cancer Res. 1986 Sep;46(9):4866-72 [3015400.001]
  • [Cites] Acta Pathol Jpn. 1986 Sep;36(9):1307-18 [3788560.001]
  • [Cites] Cancer. 1995 Mar 15;75(6 Suppl):1410-7 [7889467.001]
  • [Cites] Int J Cancer. 1997 Feb 20;74(1):112-21 [9036879.001]
  • [Cites] Virchows Arch. 1997 Aug;431(2):103-10 [9293891.001]
  • [Cites] Hum Pathol. 1999 Jul;30(7):826-32 [10414502.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] J Gastroenterol. 2004 Dec;39(12):1143-9 [15622477.001]
  • [Cites] Br J Surg. 2005 Apr;92(4):454-62 [15609380.001]
  • [Cites] Histopathology. 2005 Oct;47(4):357-67 [16178890.001]
  • [Cites] Gastric Cancer. 2005;8(4):220-7 [16328596.001]
  • [Cites] Scand J Gastroenterol. 2006 Aug;41(8):880-6 [16803685.001]
  • [Cites] World J Gastroenterol. 2006 Jun 28;12(24):3803-9 [16804962.001]
  • [Cites] Eur J Histochem. 2006 Oct-Dec;50(4):301-9 [17213039.001]
  • [Cites] Virchows Arch. 2001 Jan;438(1):49-56 [11213835.001]
  • (PMID = 20533596.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucins; 0 / Protein Isoforms
  • [Other-IDs] NLM/ PMC2883132
  •  go-up   go-down


67. Osunkoya AO, Adsay NV, Cohen C, Epstein JI, Smith SL: MUC2 expression in primary mucinous and nonmucinous adenocarcinoma of the prostate: an analysis of 50 cases on radical prostatectomy. Mod Pathol; 2008 Jul;21(7):789-94
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MUC2 expression in primary mucinous and nonmucinous adenocarcinoma of the prostate: an analysis of 50 cases on radical prostatectomy.
  • Twenty-five cases each of Gleason pattern 3 and 4 mucinous adenocarcinoma of the prostate defined by greater than 25% mucinous component and nonmucinous adenocarcinoma of the prostate were obtained from the surgical pathology files of the Johns Hopkins Hospital and Emory University Hospital.
  • MUC2 was expressed in all 25 cases (100%) of mucinous adenocarcinoma of the prostate, irrespective of the Gleason pattern.
  • In contrast, MUC2 expression was significantly lower in nonmucinous adenocarcinoma of the prostate, detected in only 6/25 cases as a focal finding, while 19/25 (76%) of nonmucinous adenocarcinoma of the prostate were completely negative for MUC2 (P<0.01).
  • Mucinous adenocarcinoma of the prostate shows diffuse expression of MUC2, a known tumor suppressor, which is not present in either normal prostate or the majority of conventional adenocarcinomas of this organ.
  • This indicates that mucinous adenocarcinoma of the prostate is indeed of the 'colloid type' akin to those in other exocrine organs.
  • [MeSH-major] Adenocarcinoma, Mucinous / metabolism. Biomarkers, Tumor / metabolism. Mucins / metabolism. Prostatic Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18487999.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MUC2 protein, human; 0 / Mucin-2; 0 / Mucins
  •  go-up   go-down


68. Matsukuma KE, Mullins FM, Dietz L, Zehnder JL, Ford JM, Chun NM, Schrijver I: Hereditary diffuse gastric cancer due to a previously undescribed CDH1 splice site mutation. Hum Pathol; 2010 Aug;41(8):1200-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hereditary diffuse gastric cancer due to a previously undescribed CDH1 splice site mutation.
  • Our patient was a 52-year-old man who was diagnosed with signet ring cell gastric adenocarcinoma.
  • An extensive family history of gastric cancer raised suspicion for hereditary diffuse gastric cancer.
  • Sequencing of the patient's CDH1 gene revealed a novel point mutation in a strictly conserved splice site within intron 6, c.833-2 A > G.
  • In addition to the wild-type product, a larger product consistent with activation of a cryptic splice site within intron 6 and a smaller product shown to result from exon 7 skipping were detected.
  • In summary, we have identified a novel CDH1 mutation in a large hereditary diffuse gastric cancer kindred and identified its pathogenic mechanism.


69. Lane Z, Hansel DE, Epstein JI: Immunohistochemical expression of prostatic antigens in adenocarcinoma and villous adenoma of the urinary bladder. Am J Surg Pathol; 2008 Sep;32(9):1322-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical expression of prostatic antigens in adenocarcinoma and villous adenoma of the urinary bladder.
  • The recent description of an unusual form of urothelial-type mucinous prostatic adenocarcinoma raises a novel differential diagnosis between adenocarcinomas of the prostate and bladder, and investigation into the utility of classic prostatic immunohistochemical antigens in bladder adenocarcinoma is warranted.
  • We identified 37 primary infiltrating adenocarcinomas of the bladder, which included signet ring cell carcinomas (n=11), urachal adenocarcinomas (n=5), and enteric adenocarcinoma (n=21).
  • Also included for comparison were 3 cases, each of bladder villous adenomas and bladder adenocarcinoma in situ.
  • P501S showed moderate diffuse cytoplasmic staining in 4/37 cases (11%), including 3 enteric-type adenocarcinomas and 1 mucinous adenocarcinoma.
  • Additionally, 1 case of adenocarcinoma in situ demonstrated diffuse cytoplasmic staining for P501S.
  • The granular perinuclear staining pattern of P501S typically seen in prostatic adenocarcinoma was absent in all cases of bladder adenocarcinoma.
  • PSMA showed diffuse cytoplasmic staining in 4/37 (11%) infiltrating adenocarcinomas (including 1 signet ring carcinoma and 3 enteric-type adenocarcinomas), and in 1 case of adenocarcinoma in situ.
  • Membranous PSMA staining was evident in an additional 3 tumors, 1 urachal mucinous adenocarcinoma, 1 nonurachal mucinous and signet ring cell adenocarcinoma, and 1 nonurachal villous adenoma.
  • In conclusion, although all cases of bladder adenocarcinoma examined were negative for PSA and PSAP, the surprising finding that a subset of invasive and in situ adenocarcinomas of the bladder demonstrated immunoreactivity for P501S and PSMA should warrant caution when using these markers in differentiating prostatic from bladder adenocarcinomas.
  • The lack of granular perinuclear staining for P501S and the absence of membranous PSMA staining both favor a bladder adenocarcinoma, although rare cases of villous adenoma and adenocarcinoma did show PSMA membranous staining indistinguishable from that seen in prostate cancer.
  • Although the novel antigens P501S and PSMA are fairly specific and more sensitive in the differential diagnosis of prostate and urothelial carcinoma, care must be taken when adenocarcinomas of the bladder are considered within this differential diagnosis.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma, Villous / metabolism. Antigens, Neoplasm / biosynthesis. Urinary Bladder Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18670358.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Membrane Proteins; 0 / prostein; EC 3.1.3.2 / Acid Phosphatase; EC 3.1.3.2 / prostatic acid phosphatase; EC 3.1.3.48 / Protein Tyrosine Phosphatases; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


70. Hong SJ, Kwon KW, Kim SG, Ko BM, Ryu CB, Kim YS, Moon JH, Cho JY, Lee JS, Lee MS, Shim CS, Kim BS: Variation in expression of gastric leptin according to differentiation and growth pattern in gastric adenocarcinoma. Cytokine; 2006 Jan 21;33(2):66-71
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Variation in expression of gastric leptin according to differentiation and growth pattern in gastric adenocarcinoma.
  • We compared the expression patterns of leptin and of the long variant of the leptin receptor (Ob-Rb) between areas with non-ulcerated mucosa and with hyperplastic polyps, adenoma, or adenocarcinoma to evaluate the expression relative to different disease states.
  • Leptin and Ob-Rb were expressed in hyperplastic polyps, adenoma, and adenocarcinoma.
  • In the gastric adenocarcinoma, leptin was expressed significantly less in the poorly differentiated and diffuse-type groups than in the well-differentiated and moderately differentiated groups or in the intestinal type.
  • Based upon our findings, we suggest the possibility that leptin expression can have a pathophysiologic role about the differentiation or growth pattern of gastric adenocarcinoma.
  • A further series of experiments is necessary to elucidate the pathophysiological role of leptin in the differentiation of gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Leptin / metabolism. Stomach / metabolism. Stomach Neoplasms / metabolism. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16434209.001).
  • [ISSN] 1043-4666
  • [Journal-full-title] Cytokine
  • [ISO-abbreviation] Cytokine
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Leptin
  •  go-up   go-down


71. Ghaffarzadehgan K, Jafarzadeh M, Raziee HR, Sima HR, Esmaili-Shandiz E, Hosseinnezhad H, Taghizadeh-Kermani A, Moaven O, Bahrani M: Expression of cell adhesion molecule CD44 in gastric adenocarcinoma and its prognostic importance. World J Gastroenterol; 2008 Nov 7;14(41):6376-81
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of cell adhesion molecule CD44 in gastric adenocarcinoma and its prognostic importance.
  • AIM: To evaluate the relation of cluster of differentiation 44 (CD44) expression with clinicopathological features of gastric adenocarcinoma, and also its effect on prognosis with an emphasis on the differences between intestinal and diffuse types.
  • METHODS: From 2000 to 2006, 100 patients with gastric adenocarcinoma, who had undergone total or subtotal gastrectomy without any prior treatment, were studied.
  • Haematoxylin and eosin (HE) staining was used for histological evaluation, including the type (Lauren's classification) and grading of the tumor.
  • The expression of CD44 in the gastric adenocarcinoma mucosa and the adjacent mucosa were determined by immunohistochemistry.
  • The tumors were categorized as intestinal type (78%) or diffuse type (22%).
  • The survival analysis showed a poor prognosis of patients with CD44-positive tumors (P=0.008); and this was more prominent in the intestinal (P=0.001) rather than diffuse type.
  • CONCLUSION: Cell adhesion molecule CD44 is highly expressed in gastric adenocarcinoma.
  • CD44 expression is correlated with a poor prognosis in patients with the intestinal type of gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / immunology. Antigens, CD44 / analysis. Biomarkers, Tumor / analysis. Stomach Neoplasms / immunology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 2001 Jan;38(1):13-20 [11135041.001]
  • [Cites] Cancer Lett. 2008 Aug 8;266(2):99-115 [18381231.001]
  • [Cites] J Cell Biol. 2001 May 28;153(5):893-904 [11381077.001]
  • [Cites] J Surg Oncol. 2002 Apr;79(4):230-5 [11920780.001]
  • [Cites] Clin Exp Metastasis. 2003;20(3):195-201 [12741678.001]
  • [Cites] Anticancer Res. 2003 Mar-Apr;23(2B):1581-8 [12820426.001]
  • [Cites] World J Gastroenterol. 2004 Mar 15;10(6):776-82 [15040016.001]
  • [Cites] Arch Pathol Lab Med. 2004 Jul;128(7):765-70 [15214826.001]
  • [Cites] J Mol Histol. 2004 Mar;35(3):211-31 [15339042.001]
  • [Cites] Cancer Res. 1993 Sep 15;53(18):4197-203 [7689929.001]
  • [Cites] Cancer Lett. 1994 Aug 15;83(1-2):229-34 [7520354.001]
  • [Cites] Oncology. 1995 Jul-Aug;52(4):334-9 [7539903.001]
  • [Cites] Cancer Surv. 1995;24:19-42 [7553660.001]
  • [Cites] J Mol Med (Berl). 1995 Aug;73(8):395-401 [8528741.001]
  • [Cites] J Clin Pathol. 1998 Feb;51(2):134-7 [9602687.001]
  • [Cites] Cancer. 1998 Sep 15;83(6):1094-101 [9740073.001]
  • [Cites] Mol Pathol. 1998 Aug;51(4):191-200 [9893744.001]
  • [Cites] J Surg Oncol. 1999 May;71(1):22-8 [10362087.001]
  • [Cites] Mol Pathol. 1999 Feb;52(1):25-8 [10439835.001]
  • [Cites] BMC Gastroenterol. 2004 Oct 27;4:28 [15509297.001]
  • [Cites] Folia Histochem Cytobiol. 2005;43(1):31-6 [15871560.001]
  • [Cites] Gene. 2005 Oct 24;360(1):1-19 [16154715.001]
  • [Cites] World J Gastroenterol. 2005 Nov 14;11(42):6601-6 [16425351.001]
  • [Cites] World J Gastroenterol. 2006 Jan 7;12(1):36-42 [16440414.001]
  • [Cites] World J Gastroenterol. 2006 Jan 14;12(2):192-8 [16482617.001]
  • [Cites] World J Gastroenterol. 2007 Oct 28;13(40):5367-70 [17879408.001]
  • [Cites] J Surg Res. 2008 May 1;146(1):149-58 [17720195.001]
  • [Cites] World J Gastroenterol. 2008 Apr 7;14(13):2055-60 [18395906.001]
  • [Cites] Trends Mol Med. 2001 May;7(5):213-21 [11325633.001]
  • (PMID = 19009655.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Biomarkers, Tumor; 0 / CD44 protein, human
  • [Other-IDs] NLM/ PMC2766121
  •  go-up   go-down


72. Kato Y, Yashiro M, Noda S, Kashiwagi S, Matsuoka J, Fuyuhiro Y, Doi Y, Hirakawa K: Expression of a hypoxia-associated protein, carbonic anhydrase-9, correlates with malignant phenotypes of gastric carcinoma. Digestion; 2010;82(4):246-51
figshare. supplemental materials - Supporting Data and Materials for the article .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of a hypoxia-associated protein, carbonic anhydrase-9, correlates with malignant phenotypes of gastric carcinoma.
  • The purpose of our study was to clarify the significance of hypoxia in gastric carcinoma by evaluating the expression of a hypoxic marker, namely carbonic anhydrase-9 (CA-9).
  • The CA-9 expression level was significantly high in cases of type 4 carcinoma (60%, p < 0.001) and diffuse type carcinoma (41%, p < 0.001), and significantly correlated with the invasion depth (p < 0.001), lymph node metastasis (p < 0.001) and lymphatic invasion p = 0.002).
  • [MeSH-major] Adenocarcinoma / metabolism. Carbonic Anhydrases / biosynthesis. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20588040.001).
  • [ISSN] 1421-9867
  • [Journal-full-title] Digestion
  • [ISO-abbreviation] Digestion
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 4.2.1.1 / Carbonic Anhydrases
  •  go-up   go-down


73. Teh SK, Zheng W, Ho KY, Teh M, Yeoh KG, Huang Z: Near-infrared Raman spectroscopy for early diagnosis and typing of adenocarcinoma in the stomach. Br J Surg; 2010 Apr;97(4):550-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Near-infrared Raman spectroscopy for early diagnosis and typing of adenocarcinoma in the stomach.
  • BACKGROUND: The aim of this study was to evaluate the feasibility of using near-infrared (NIR) Raman spectroscopy for early diagnosis and typing of intestinal and diffuse adenocarcinoma of the stomach.
  • METHODS: A dispersive-type NIR Raman system was used for tissue measurements.
  • There were significant differences in Raman spectra between normal stomach and the two gastric adenocarcinoma subtypes, particularly in the spectral ranges 850-1150, 1200-1500 and 1600-1750 cm(-1), which contain signals related to proteins, nucleic acids and lipids.
  • PCA-MNLR achieved predictive accuracies of 88, 92 and 94 per cent for normal stomach, and intestinal- and diffuse-type gastric adenocarcinomas respectively.
  • CONCLUSION: NIR Raman spectroscopy can detect gastric malignancy and identify the subtype of gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Stomach Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.
  • (PMID = 20155786.001).
  • [ISSN] 1365-2168
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


74. Meng ZL, Guo LN, Luo YF, Cao JL, Wan JW, Liu TH: [Role of HPV DNA detection and p16(INK4A) protein expression in diagnosis of endocervical adenocarcinoma]. Zhonghua Bing Li Xue Za Zhi; 2007 Dec;36(12):810-3
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Role of HPV DNA detection and p16(INK4A) protein expression in diagnosis of endocervical adenocarcinoma].
  • OBJECTIVES: To evaluate the significance of p16(INK4A) protein expression and positivity for HPV DNA in distinguishing between endocervical and endometrial adenocarcinoma.
  • METHODS: Expression of p16(INK4A) protein in 30 cases of endocervical adenocarcinoma and 10 cases of endometrial adenocarcinoma was assessed by immunohistochemistry.
  • In-situ hybridization for human papillomavirus (HPV) DNA was also performed in 20 cases of endocervical adenocarcinoma and 10 cases of endometrial adenocarcinoma.
  • RESULTS: The positive rate for p16(INK4A) in endocervical adenocarcinoma was 70% (21/30), as compared with 30% (3/10) in endometrial adenocarcinoma.
  • The tumor cells in endocervical adenocarcinoma showed diffuse and strong expression of p16(INK4A) protein with both cytoplasmic and nuclear staining.
  • In contrast, the endometrial adenocarcinoma cells showed patchy and weak expression of p16(INK4A).
  • On the other hand, HPV DNA (type 16 or 18) was detected by in-situ hybridization in 9 (45%) of the 20 cases of endocervical adenocarcinoma and none of the 10 cases of endometrial adenocarcinoma.
  • CONCLUSIONS: The expression of p16(INK4A) protein is significantly higher in endocervical adenocarcinoma than in endometrial adenocarcinoma.
  • This expression pattern can serve as a useful immunohistochemical marker in the differential diagnosis. p16(INK4A) protein immunohistochemistry appears to be more sensitive than HPV DNA testing in distinguishing between endocervical and endometrial adenocarcinoma, especially in biopsy or curettage specimens.
  • [MeSH-major] Adenocarcinoma / diagnosis. Cyclin-Dependent Kinase Inhibitor p16 / genetics. DNA, Viral / analysis. Gene Expression Regulation, Neoplastic. Human papillomavirus 16 / genetics. Human papillomavirus 18 / genetics. Uterine Cervical Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18346352.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA, Viral
  •  go-up   go-down


75. Calcagno DQ, Leal MF, Taken SS, Assumpção PP, Demachki S, Smith Mde A, Burbano RR: Aneuploidy of chromosome 8 and C-MYC amplification in individuals from northern Brazil with gastric adenocarcinoma. Anticancer Res; 2005 Nov-Dec;25(6B):4069-74
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aneuploidy of chromosome 8 and C-MYC amplification in individuals from northern Brazil with gastric adenocarcinoma.
  • BACKGROUND: Gastric cancer is the third most frequent type of neoplasia.
  • In northern Brazil, the State of Pará has a high incidence of this type of neoplasia.
  • RESULTS: All cases showed aneuploidy of chromosome 8 and C-MYC amplification, in both the diffuse and the intestinal histopathological types of Laurén.
  • C-MYC amplification, like homogeneously-stained regions (HSRs) and double minutes (DMs), was observed only in the intestinal-type.
  • Translocation of C-MYC was observed only in the diffuse-type.
  • CONCLUSION: Chromosome 8 can be used as a marker in the diagnosis of gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Aneuploidy. Chromosomes, Human, Pair 8 / genetics. Genes, myc / genetics. Stomach Neoplasms / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Anticancer Res. 2006 Jan-Feb;26(1a):445
  • (PMID = 16309200.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  •  go-up   go-down


76. Lehrbach DM, Cecconello I, Ribeiro Jr U, Capelozzi VL, Ab'saber AM, Alves VA: Adenocarcinoma of the esophagogastric junction: relationship between clinicopathological data and p53, cyclin D1 and Bcl-2 immunoexpressions. Arq Gastroenterol; 2009 Oct-Dec;46(4):315-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the esophagogastric junction: relationship between clinicopathological data and p53, cyclin D1 and Bcl-2 immunoexpressions.
  • CONTEXT: Esophagogastric junction adenocarcinoma has an aggressive behavior, and TNM (UICC) staging is not always accurate enough to categorize patient's outcome.
  • OBJECTIVES: To evaluated p53, cyclin D1 and Bcl-2 immunoexpressions in esophagogastric junction adenocarcinoma patients, without Barrett's esophagus, and to compared to clinicopathological characteristics and survival rate.
  • RESULTS: Fifty (66.7%) of the tumors were intestinal type and 25 (33.3%) were diffuse.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20232013.001).
  • [ISSN] 1678-4219
  • [Journal-full-title] Arquivos de gastroenterologia
  • [ISO-abbreviation] Arq Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53; 136601-57-5 / Cyclin D1
  •  go-up   go-down


77. Norton JA, Ham CM, Van Dam J, Jeffrey RB, Longacre TA, Huntsman DG, Chun N, Kurian AW, Ford JM: CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer. Ann Surg; 2007 Jun;245(6):873-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer.
  • E-cadherin (CDH1) truncating mutations have been shown to be present in approximately 30% of families with hereditary diffuse gastric cancer (HDGC) and are associated with a significantly increased risk of gastric cancer and lobular breast cancer.
  • However, each patient (6 of 6, 100%) was found to have multiple foci of T1 invasive diffuse gastric adenocarcinoma (pure signet-ring cell type).
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / surgery. Cadherins / genetics. Gastrectomy. Mutation. Stomach Neoplasms / genetics. Stomach Neoplasms / surgery
  • [MeSH-minor] Anastomosis, Roux-en-Y. Biopsy. Breast Neoplasms / genetics. Breast Neoplasms / prevention & control. Carcinoma, Signet Ring Cell / genetics. Carcinoma, Signet Ring Cell / pathology. Carcinoma, Signet Ring Cell / surgery. Diagnostic Imaging. Female. Gastroscopy. Humans. Lymph Node Excision. Male. Middle Aged. Neoplasm Staging. Occult Blood. Pedigree. Primary Prevention. Prospective Studies. Quality of Life. Treatment Outcome


78. Chu PG, Schwarz RE, Lau SK, Yen Y, Weiss LM: Immunohistochemical staining in the diagnosis of pancreatobiliary and ampulla of Vater adenocarcinoma: application of CDX2, CK17, MUC1, and MUC2. Am J Surg Pathol; 2005 Mar;29(3):359-67
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical staining in the diagnosis of pancreatobiliary and ampulla of Vater adenocarcinoma: application of CDX2, CK17, MUC1, and MUC2.
  • We studied the expression of cytokeratin 7 (CK7), cytokeratin 17 (CK17), cytokeratin 20 (CK20), CDX2, mucin 1 (MUC1), mucin 2 (MUC2), and mucin 5AC (MUC5AC) in 46 cases of pancreatic ductal carcinoma, 18 ampulla of Vater adenocarcinomas, and 24 intrahepatic cholangiocarcinomas.
  • The expression of MUC1 and CK17 was restricted to pancreatic ductal carcinoma (41 of 46, 89%; 38 of 46, 83%, respectively), the ampullary carcinoma of pancreatobiliary origin (6 of 6, 100%; 5 of 6, 83%, respectively), and intrahepatic cholangiocarcinoma (20 of 24, 83%; 17 of 24, 71%, respectively).
  • More than 50% of cases of pancreatobiliary adenocarcinomas showed diffuse cytoplasmic CK17 positivity.
  • In contrast, less than 5% cases (8 of 184) of extra-pancreatobiliary nonmucinous adenocarcinomas expressed CK17, and only 3 of them showed diffuse CK17 positivity.
  • The expression of MUC2 and CDX2 was restricted to the intestinal, mucinous, and signet-ring cell-type adenocarcinomas of duodenal papillary origin (9 of 11, 82%; 11 of 11, 100%, respectively).
  • MUC2 was rarely expressed in pancreatic ductal carcinoma (1 of 46, 2%) and was negative in the ampullary carcinoma of pancreatobiliary origin and in intrahepatic cholangiocarcinoma.
  • A heterogeneous CDX2 staining pattern was seen in 1 of 6 cases of the ampullary carcinoma of pancreatobiliary origin (17%), 5 of 24 intrahepatic cholangiocarcinomas (21%), and 10 of 46 (22%) pancreatic ductal carcinomas.
  • In contrast, all 11 cases of the intestinal, mucinous, and signet-ring cell-type adenocarcinomas of duodenal papillary origin showed homogeneous CDX2 nuclear positivity.
  • MUC1+/CK17+ can be used as positive markers for pancreatic ductal carcinomas, the ampullary carcinoma of pancreatobiliary origin, and cholangiocarcinomas with positive predictive values of 76%, 83%, and 58%, respectively.
  • MUC2+/CDX2+ can be used as positive markers for the intestinal-type adenocarcinoma of duodenal papillary origin with a positive predictive value of 82%.
  • [MeSH-major] Ampulla of Vater / pathology. Bile Ducts, Intrahepatic / pathology. Carcinoma, Pancreatic Ductal / pathology. Cholangiocarcinoma / pathology. Common Bile Duct Neoplasms / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Biomarkers, Tumor / metabolism. Female. Homeodomain Proteins / metabolism. Humans. Immunohistochemistry. Keratins / metabolism. Male. Mucins / metabolism. Neoplasm Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15725805.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDX2 protein, human; 0 / Homeodomain Proteins; 0 / Mucins; 0 / Neoplasm Proteins; 68238-35-7 / Keratins
  •  go-up   go-down


79. Agaimy A, Märkl B, Arnholdt H, Hartmann A, Schneider-Stock R, Chetty R: Sporadic segmental Interstitial cell of cajal hyperplasia (microscopic GIST) with unusual diffuse longitudinal growth replacing the muscularis propria: differential diagnosis to hereditary GIST syndromes. Int J Clin Exp Pathol; 2010;3(5):549-56
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sporadic segmental Interstitial cell of cajal hyperplasia (microscopic GIST) with unusual diffuse longitudinal growth replacing the muscularis propria: differential diagnosis to hereditary GIST syndromes.
  • However, patients with germline mutations in c-KIT, PDGFRA and NF1 may present with diffuse interstitial cell of Cajal (ICC) hyperplasia along the Auer-bach plexus without forming a discrete mass.
  • To our knowledge, sporadic diffuse ICC hyperplasia replacing the gut wall has not been described previously.
  • The diverticular component showed a diffuse proliferation of spindle cells extending for several centimetres from the solid tumor replacing the full thickness of the gut wall and lined by intact mucosa.
  • Mutation analysis revealed a combined deletion/insertion in c-KIT exon 11 (V560delEins) in both the solid and the diffuse tumor component.
  • Case 2 was a 66-yr-old man who underwent segmental sigmoid colon resection for adenocarcinoma in a villous adenoma.
  • Random sections from grossly unremarkable colonic wall showed a diffuse proliferation of CD117+/CD34+ spindle cells completely replacing the muscularis propria for a length of 6 mm.
  • Absence of multiple lesions and demonstration of a wild-type sequence for c-KIT in surrounding normal tissue ruled out the possibility of a germline mutation in both cases.
  • This peculiar diffuse form of sporadic ICC hyperplasia results from somatic c-KIT mutations and must be distinguished from syndromic ICC hyperplasia associated with hereditary GIST syndromes.

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2000 Feb;24(2):326-7 [10680913.001]
  • [Cites] Virchows Arch. 2009 Aug;455(2):101-8 [19572146.001]
  • [Cites] Mod Pathol. 2002 Feb;15(2):125-36 [11850541.001]
  • [Cites] Am J Pathol. 2002 May;160(5):1567-72 [12000708.001]
  • [Cites] Gut. 2002 Dec;51(6):793-6 [12427778.001]
  • [Cites] Science. 2003 Jan 31;299(5607):708-10 [12522257.001]
  • [Cites] J Pathol. 2004 Jan;202(1):80-5 [14694524.001]
  • [Cites] Gastroenterology. 2004 Jan;126(1):318-21 [14699510.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):3076-81 [15131046.001]
  • [Cites] J Mol Diagn. 2004 Aug;6(3):197-204 [15269295.001]
  • [Cites] Am J Surg Pathol. 1993 Jul;17(7):706-14 [8317611.001]
  • [Cites] Science. 1998 Jan 23;279(5350):577-80 [9438854.001]
  • [Cites] Am J Pathol. 1998 May;152(5):1259-69 [9588894.001]
  • [Cites] Cancer. 2005 Feb 15;103(4):821-9 [15648083.001]
  • [Cites] Am J Surg Pathol. 2006 Jan;30(1):90-6 [16330947.001]
  • [Cites] Virchows Arch. 2006 Mar;448(3):288-94 [16308708.001]
  • [Cites] Langenbecks Arch Surg. 2006 Aug;391(4):322-9 [16402273.001]
  • [Cites] Hum Pathol. 2006 Dec;37(12):1527-35 [16996566.001]
  • [Cites] Semin Diagn Pathol. 2006 May;23(2):70-83 [17193820.001]
  • [Cites] Am J Surg Pathol. 2007 Jan;31(1):113-20 [17197927.001]
  • [Cites] Histopathology. 2007 Jan;50(2):190-202 [17222247.001]
  • [Cites] Am J Surg Pathol. 2007 Jun;31(6):933-7 [17527083.001]
  • [Cites] Pathology. 2008 Jan;40(1):9-12 [18038309.001]
  • [Cites] Am J Surg Pathol. 2007 Nov;31(11):1629-35 [18059218.001]
  • [Cites] Endoscopy. 2007 Feb;39 Suppl 1:E142-3 [17611891.001]
  • [Cites] Int J Cancer. 2008 May 1;122(9):2160-4 [18183595.001]
  • [Cites] Am J Surg Pathol. 2008 Jun;32(6):867-73 [18408593.001]
  • [Cites] Am J Surg Pathol. 2008 Oct;32(10):1553-9 [18724245.001]
  • [Cites] World J Surg Oncol. 2009;7:33 [19309498.001]
  • [Cites] JBR-BTR. 2009 Jan-Feb;92(1):23-4 [19358482.001]
  • [Cites] Am J Surg Pathol. 2000 Nov;24(11):1568-72 [11075862.001]
  • (PMID = 20606738.001).
  • [ISSN] 1936-2625
  • [Journal-full-title] International journal of clinical and experimental pathology
  • [ISO-abbreviation] Int J Clin Exp Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  • [Other-IDs] NLM/ PMC2897106
  • [Keywords] NOTNLM ; GIST / ICC hyperplasia / KIT mutation / Meckel Diverticulum / hereditary GIST
  •  go-up   go-down


80. Wang YK, Zhao W, Hao Y, Zhang Y, Guo YB, Meng NL, Ma L, Li J: [Clinicopathologic features of gallbladder adenocarcinoma with marked stromal fibrosis--a report of 19 cases]. Ai Zheng; 2006 Jul;25(7):896-900
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic features of gallbladder adenocarcinoma with marked stromal fibrosis--a report of 19 cases].
  • BACKGROUND & OBJECTIVE: Macropathologic types of gallbladder cancer are mostly polyp type, intumescent type, and cauliflower form lump.
  • Its histological types include well or poorly differentiated adenocarcinoma, mucinous adenocarcinoma, and undifferentiated cancer.
  • This research was to explore the clinicopathologic features of gallbladder adenocarcinoma with marked stromal fibrosis.
  • METHODS: Pathology of 19 cases of gallbladder adenocarcinoma with marked stromal fibrosis was observed using a light microscopy and SP immunohistochemistry.
  • Observed with naked eyes, gallbladder adenocarcinoma with marked stromal fibrosis did not form cancer nodule and extrude into the gallbladder lumen, the gallbladder wall showed regional thickening, a few cases showed diffuse irregular thickening.
  • Observed under a light microscope, the adenocarcinoma cells were mostly arranged as single layers, seldom arranged as multiple layers, and formed adenoid structures with different sizes, various shapes, and irregular arrangement; the nuclei were heterogenic with haryomitosis presented in a few cases; inflammatory cells were infiltrated in hyperplastic fibrous connective tissue of some cases.
  • CONCLUSIONS: The clinical manifestation, macropathologic type, histological characteristics of gallbladder adenocarcinoma with stromal fibrosis are different from other types of adenocarcinoma.
  • Its genesis may be related to chronic cholecystitis: long-term inflammation causes regional hyperplasia and heterogeneity of the gland body, lead to focal or regional thickening of the gallbladder wall, and result in gallbladder adenocarcinoma with stromal fibrosis finally.
  • [MeSH-major] Adenocarcinoma / pathology. Gallbladder / pathology. Gallbladder Neoplasms / pathology. Keratins / metabolism

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16831286.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 68238-35-7 / Keratins
  •  go-up   go-down


81. Feng W, Brown RE, Trung CD, Li W, Wang L, Khoury T, Alrawi S, Yao J, Xia K, Tan D: Morphoproteomic profile of mTOR, Ras/Raf kinase/ERK, and NF-kappaB pathways in human gastric adenocarcinoma. Ann Clin Lab Sci; 2008;38(3):195-209
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Morphoproteomic profile of mTOR, Ras/Raf kinase/ERK, and NF-kappaB pathways in human gastric adenocarcinoma.
  • Preclinical studies using human gastric adenocarcinoma (GAC) cell lines have shown that the mammalian target of rapamycin (mTOR) inhibitor, rapamycin, can inhibit tumor growth and that the extracellular signal-regulated kinase (ERK) of the Ras/Raf kinase/ERK pathway is related to chemoresistance and apoptosis.
  • Additionally, there were statistically significant differences in the mean expression levels of p-ERK-1/2 and p-NF-kappaBp65 in diffuse vs intestinal types of GAC, with higher levels of both in the diffuse type ( p = 0.001 and p <0.0001, respectively).
  • [MeSH-minor] Adenocarcinoma / enzymology. Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Calcium-Binding Proteins / metabolism. Female. Gastric Mucosa / enzymology. Gastric Mucosa / pathology. Humans. Immunohistochemistry. Ki-67 Antigen / metabolism. Male. Middle Aged. Neoplasm Proteins / metabolism. Phosphoproteins / metabolism. Ribosomal Protein S6 Kinases, 70-kDa / metabolism. S-Phase Kinase-Associated Proteins / metabolism. TOR Serine-Threonine Kinases. Transcription Factor RelA / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18715846.001).
  • [ISSN] 1550-8080
  • [Journal-full-title] Annals of clinical and laboratory science
  • [ISO-abbreviation] Ann. Clin. Lab. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Calcium-Binding Proteins; 0 / Ki-67 Antigen; 0 / NF-kappa B; 0 / Neoplasm Proteins; 0 / Phosphoproteins; 0 / S-Phase Kinase-Associated Proteins; 0 / S100P protein, human; 0 / Transcription Factor RelA; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.11.1 / Ribosomal Protein S6 Kinases, 70-kDa; EC 2.7.11.1 / raf Kinases; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


82. Lisovsky M, Dresser K, Baker S, Fisher A, Woda B, Banner B, Lauwers GY: Cell polarity protein Lgl2 is lost or aberrantly localized in gastric dysplasia and adenocarcinoma: an immunohistochemical study. Mod Pathol; 2009 Jul;22(7):977-84
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell polarity protein Lgl2 is lost or aberrantly localized in gastric dysplasia and adenocarcinoma: an immunohistochemical study.
  • The diagnosis of gastric epithelial dysplasia, a precursor lesion of gastric adenocarcinoma, is hindered by interobserver variability and by its resemblance to regenerative changes.
  • The goal of our study was to test the hypothesis that Lgl2 protein expression and/or localization are disrupted in gastric epithelial dysplasia and adenocarcinoma.
  • All but one case each of gastric epithelial dysplasia and adenocarcinoma showed either complete loss of anti-Lgl2 immunoreactivity or diffuse, mostly weak, cytoplasmic staining.
  • Complete loss of immunoreactivity was significantly more often observed in diffuse-type than in intestinal-type adenocarcinomas (79 vs 48%, respectively).
  • Our data suggest that Lgl2 expression is either aberrantly localized or lost in gastric epithelial dysplasia and adenocarcinoma, whereas it is maintained in reactive gastric mucosa.
  • We propose that Lgl2 may be a potential marker to rule out gastric epithelial dysplasia and adenocarcinoma in diagnostic specimens.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Cytoskeletal Proteins / metabolism. Gastric Mucosa / metabolism. Precancerous Conditions / metabolism. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19407852.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cytoskeletal Proteins; 0 / Hugl-2 protein, human
  •  go-up   go-down


83. Hao H, Tsujimoto M, Tsubamoto H, Komori S, Hirota S: Immunohistochemical phenotype of the urinary bladder endocervicosis: comparison with normal endocervix and well-differentiated mucinous adenocarcinoma of uterine cervix. Pathol Int; 2010 Jul;60(7):528-32
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical phenotype of the urinary bladder endocervicosis: comparison with normal endocervix and well-differentiated mucinous adenocarcinoma of uterine cervix.
  • The mass was removed and histology revealed a haphazard proliferation of endocervical-type mucinous glands scattered through the muscularis propria of bladder wall.
  • Immunohistochemical phenotype of these glands was compared with three normal uterine endocervices and two cases of well-differentiated mucinous adenocarcinoma of the uterine cervix.
  • On the other hand, only glands of well-differentiated mucinous adenocarcinoma expressed human gastric mucin and showed high proliferative index of Ki-67.
  • Furthermore, diffuse distribution of estrogen and progesterone receptors, lack of human gastric mucin and low proliferative activity were distinct features for endocervicosis compared to well-differentiated mucinous adenocarcinoma.
  • [MeSH-minor] Adenocarcinoma, Mucinous / pathology. Adult. Cesarean Section. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Phenotype. Pregnancy. Uterine Cervical Neoplasms / metabolism. Uterine Cervical Neoplasms / pathology


84. Lee SK, Moon J, Park SW, Song SY, Chung JB, Kang JK: Loss of the tight junction protein claudin 4 correlates with histological growth-pattern and differentiation in advanced gastric adenocarcinoma. Oncol Rep; 2005 Feb;13(2):193-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of the tight junction protein claudin 4 correlates with histological growth-pattern and differentiation in advanced gastric adenocarcinoma.
  • Western blot analysis and RT-PCR were performed in representative tumors of the diffuse or intestinal type.
  • According to the Lauren classification, the reduced expression of E-cadherin and claudin 4 was more frequent in diffuse than intestinal type tumors (p<0.001).
  • Western blot analysis and RT-PCR also showed decreased claudin 4 expression in diffuse type tumors and poorly-differentiated adenocarcinoma.
  • The reduced expression of claudin 4 and E-cadherin correlates with disruption of glandular structure and loss of differentiation, which suggests that the dysfunction of claudin 4 may play a role in the disruption of cell-to-cell adhesion in diffuse type gastric cancer and in a loss of differentiation.
  • [MeSH-major] Adenocarcinoma / metabolism. Membrane Proteins / analysis. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15643498.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / CLDN4 protein, human; 0 / Cadherins; 0 / Claudin-4; 0 / Membrane Proteins; 0 / Phosphoproteins; 0 / TJP1 protein, human; 0 / Zonula Occludens-1 Protein
  •  go-up   go-down


85. Van Domselaar F, Correa D, Vaccaro C, Redal M, Van Domselaar R, Huntsman D, Kaurah P, Senz J, Lynch H: [Hereditary diffuse gastric cancer (HDGC): presentation of a family with a new mutation of the CDH1 gene]. Acta Gastroenterol Latinoam; 2007 Sep;37(3):158-63
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hereditary diffuse gastric cancer (HDGC): presentation of a family with a new mutation of the CDH1 gene].
  • [Transliterated title] Cáncer gástrico difuso hereditario (CGDH): presentación de una familia con una nueva mutación del gen CDH1.
  • CASE: 28 year-old woman who underwent gastrectomy for a diffuse type gastric cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Cadherins / genetics. Mutation. Stomach Neoplasms / genetics


86. Boroumand-Noughabi S, Sima HR, Ghaffarzadehgan K, Jafarzadeh M, Raziee HR, Hosseinnezhad H, Moaven O, Rajabi-Mashhadi MT, Azarian AA, Mashhadinejad M, Tavakkol-Afshari J: Soluble Fas might serve as a diagnostic tool for gastric adenocarcinoma. BMC Cancer; 2010;10:275
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soluble Fas might serve as a diagnostic tool for gastric adenocarcinoma.
  • We have compared the serum levels of sFas/sFasL in gastric adenocarcinoma patients and cases with pre-neoplastic lesions as potential markers for early diagnosis, and investigated their relation with clinicopathological characteristics.
  • METHODS: Fifty-nine newly-diagnosed cases of gastric adenocarcinoma who had undergone gastrectomy, along with 62 endoscopically- and histologically-confirmed non-cancer individuals were enrolled in this study. sFas/sFasL serum levels were detected by Enzyme Linked Immunosurbent Assay.
  • RESULTS: Mean serum sFas level was significantly higher in gastric cancer patients than in control group (305.97 +/- 63.71 (pg/ml) vs. 92.98 +/- 4.95 (pg/ml), P < 0.001); while the mean serum level of sFasL was lower in patients with gastric adenocarcinoma (0.138 +/- 0.04 (pg/ml) vs. 0.150 +/- 0.02 (pg/ml), P < 0.001).
  • Mean serum levels of sFas/sFasL were significantly different in both intestinal/diffuse and cardiac/non-cardiac subtypes when compared to the control group (P < 0.001).
  • There was an increase in the serum level of sFas from the first steps of pre-neoplastic lesions to gastric adenocarcinoma (P < 0.001).
  • CONCLUSIONS: Production of sFas may play a critical role in the carcinogenesis of intestinal-type gastric cancer. sFas serum level may serve as a non-invasive tool for early diagnosis of gastric cancer.
  • [MeSH-major] Adenocarcinoma / blood. Antigens, CD95 / blood. Biomarkers, Tumor / blood. Fas Ligand Protein / blood. Stomach Neoplasms / blood

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Leukoc Biol. 2002 Jun;71(6):907-20 [12050175.001]
  • [Cites] Toxicol Appl Pharmacol. 2001 Aug 1;174(3):264-72 [11485387.001]
  • [Cites] Ai Zheng. 2002 Feb;21(2):174-6 [12479070.001]
  • [Cites] World J Gastroenterol. 2003 Jul;9(7):1415-20 [12854132.001]
  • [Cites] Beijing Da Xue Xue Bao. 2003 Aug;35(4):386-9 [12947554.001]
  • [Cites] Semin Immunol. 2003 Jun;15(3):145-57 [14563113.001]
  • [Cites] Science. 1994 Mar 25;263(5154):1759-62 [7510905.001]
  • [Cites] Nature. 1995 Feb 2;373(6513):444-8 [7530337.001]
  • [Cites] J Immunol. 1995 Mar 15;154(6):2706-13 [7533181.001]
  • [Cites] Nat Med. 1996 Mar;2(3):317-22 [8612231.001]
  • [Cites] Am J Surg Pathol. 1996 Oct;20(10):1161-81 [8827022.001]
  • [Cites] Gut. 1999 Feb;44(2):156-62 [9895372.001]
  • [Cites] Ann Surg. 2005 Jan;241(1):27-39 [15621988.001]
  • [Cites] J Periodontol. 2005 May;76(5):737-9 [15898934.001]
  • [Cites] Chem Biol Interact. 2005 Jun 30;155(1-2):31-42 [15970277.001]
  • [Cites] J Epidemiol. 2005 Jun;15 Suppl 2:S120-5 [16127223.001]
  • [Cites] Lancet Oncol. 2006 Dec;7(12):1006-16 [17138222.001]
  • [Cites] J Immunol. 2008 Apr 1;180(7):4668-78 [18354190.001]
  • [Cites] J Surg Res. 2008 Aug;148(2):143-51 [18561948.001]
  • [Cites] Adv Med Sci. 2008;53(1):49-53 [18614439.001]
  • [Cites] Int J Cancer. 2008 Oct 15;123(8):1913-6 [18688865.001]
  • [Cites] Br J Cancer. 2008 Nov 18;99(10):1600-6 [18941456.001]
  • [Cites] Curr Drug Targets. 2009 Feb;10(2):94-103 [19199904.001]
  • [Cites] Ann Oncol. 2009 Mar;20(3):556-63 [19073863.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Br J Haematol. 1999 Dec;107(4):851-60 [10606894.001]
  • [Cites] Int J Mol Med. 2000 May;5(5):473-6 [10762649.001]
  • [Cites] Br J Cancer. 2000 Apr;82(8):1446-52 [10780525.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2448-55 [10873098.001]
  • [Cites] Nature. 2000 Oct 12;407(6805):789-95 [11048730.001]
  • [Cites] Cancer. 2000 Dec 15;89(12):2560-4 [11135216.001]
  • [Cites] Ann Surg Oncol. 2000 Dec;7(10):750-7 [11129423.001]
  • [Cites] Oncol Rep. 2001 Mar-Apr;8(2):311-4 [11182046.001]
  • [Cites] Cell. 2001 Feb 23;104(4):487-501 [11239407.001]
  • [Cites] Cancer. 2001 Jul 15;92(2):287-93 [11466681.001]
  • [Cites] Clin Cancer Res. 2002 Aug;8(8):2553-62 [12171883.001]
  • (PMID = 20534173.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / Biomarkers, Tumor; 0 / FAS protein, human; 0 / FASLG protein, human; 0 / Fas Ligand Protein
  • [Other-IDs] NLM/ PMC2906478
  •  go-up   go-down


87. Zheng HC, Tsuneyama K, Takahashi H, Miwa S, Sugiyama T, Popivanova BK, Fujii C, Nomoto K, Mukaida N, Takano Y: Aberrant Pim-3 expression is involved in gastric adenoma-adenocarcinoma sequence and cancer progression. J Cancer Res Clin Oncol; 2008 Apr;134(4):481-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant Pim-3 expression is involved in gastric adenoma-adenocarcinoma sequence and cancer progression.
  • RESULTS: Pim-3 expression was enhanced in adenoma (64.6%) and metastasis sites of gastric carcinoma (73.0%), to a lesser degree in primary sites of gastric carcinoma (39.3%) when compared to non-cancerous mucosa (13.1%, p < 0.0001).
  • Pim-3 expression levels were higher in intestinal-type than diffuse-type gastric carcinoma (p = 0.018).
  • Furthermore, patients with Pim-3 positive gastric cancer, showed a lower cumulative survival rate than those with Pim-3 negative gastric cancer (p = 0.014) and Pim-3 positive was also identified as an independent prognostic factor for gastric carcinoma patients (p = 0.006).
  • CONCLUSIONS: Aberrant Pim-3 expression was involved in gastric adenoma-adenocarcinoma sequence and subsequent invasion and metastasis process in gastric cancer.
  • Distinct Pim-3 expression underlies the molecular mechanisms for the differentiation of intestinal-type and diffuse-type carcinomas.
  • [MeSH-major] Adenocarcinoma / chemistry. Adenoma / chemistry. Protein-Serine-Threonine Kinases / analysis. Proto-Oncogene Proteins / analysis. Stomach Neoplasms / chemistry

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17876606.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Proto-Oncogene Proteins; 0 / Vascular Endothelial Growth Factor A; EC 2.7.11.1 / PIM3 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


88. Palestro G, Pellicano R, Fronda GR, Valente G, De Giuli M, Soldati T, Pugliese A, Taraglio S, Garino M, Campra D, Cutufia MA, Margaria E, Spinzi G, Ferrara A, Marenco G, Rizzetto M, Ponzetto A: Prevalence of Helicobacter pylori infection and intestinal metaplasia in subjects who had undergone surgery for gastric adenocarcinoma in Northwest Italy. World J Gastroenterol; 2005 Dec 7;11(45):7131-5
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence of Helicobacter pylori infection and intestinal metaplasia in subjects who had undergone surgery for gastric adenocarcinoma in Northwest Italy.
  • METHODS: Samples from 317 (184 males, 133 females, mean age 69+/-3.4 years) consecutive patients who had undergone surgery for gastric non-cardia adenocarcinoma were included in the study.
  • There was no difference between the frequency of H pylori in intestinal type carcinoma (76.2%) and diffuse type cancer (78.8%).
  • Intestinal metaplasia (IM) was more frequent but not significant in the intestinal type cancer (83.4% vs 75.2% in diffuse type and 72.5% in mixed type).
  • Among the patients examined for IM, 39.8% had IM type I, 8.3% type II and 51.9% type III(type III vs others, P = 0.4).
  • CONCLUSION: This study confirms a high seroprevalence of H pylori infection in patients suffering from gastric adenocarcinoma and provides further evidence that searching for CagA status over H pylori infection might confer additional benefit in identifying populations at greater risk for this tumor.
  • [MeSH-major] Adenocarcinoma / complications. Helicobacter Infections / complications. Helicobacter Infections / epidemiology. Helicobacter pylori. Intestines / pathology. Stomach Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16437659.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibodies, Bacterial; 0 / Antigens, Bacterial; 0 / Bacterial Proteins; 0 / cagA protein, Helicobacter pylori
  • [Other-IDs] NLM/ PMC4725078
  •  go-up   go-down


89. Mikami Y, Kiyokawa T, Moriya T, Sasano H: Immunophenotypic alteration of the stromal component in minimal deviation adenocarcinoma ('adenoma malignum') and endocervical glandular hyperplasia: a study using oestrogen receptor and alpha-smooth muscle actin double immunostaining. Histopathology; 2005 Feb;46(2):130-6
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunophenotypic alteration of the stromal component in minimal deviation adenocarcinoma ('adenoma malignum') and endocervical glandular hyperplasia: a study using oestrogen receptor and alpha-smooth muscle actin double immunostaining.
  • AIMS: To define the phenotypic alteration of the stromal component in association with destructive invasion which is a crucial feature in distinguishing minimal deviation adenocarcinoma (MDA) from benign endocervical glandular lesions.
  • METHODS AND RESULTS: We studied endocervical glandular hyperplasias including non-specific-type (NEGH) (n = 3) and lobular-type (LEGH) (n = 8), and minimal deviation adenocarcinoma (MDA) (n = 11), well-differentiated endocervical adenocarcinoma of usual-type (WDA) (n = 11), and adenocarcinoma in situ (AIS) (n = 6) of the cervix, by double immunostaining for oestrogen receptor (ER) and alpha-smooth muscle actin (alpha-SMA) using peroxidase- and alkaline phosphatase-polymer methods, respectively.
  • The distribution of alpha-SMA+ cells was periglandular (6/11), patchy (6/11), and/or diffuse (4/11) in WDA, whereas in MDA it was periglandular (11/11) and/or patchy (8/11).
  • [MeSH-major] Actins / analysis. Adenocarcinoma / pathology. Cervix Uteri / pathology. Receptors, Estrogen / analysis. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15693884.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Actins; 0 / Receptors, Estrogen
  •  go-up   go-down


90. Bancel B, Esteve J, Souquet JC, Toyokuni S, Ohshima H, Pignatelli B: Differences in oxidative stress dependence between gastric adenocarcinoma subtypes. World J Gastroenterol; 2006 Feb 21;12(7):1005-12
Hazardous Substances Data Bank. L-TYROSINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differences in oxidative stress dependence between gastric adenocarcinoma subtypes.
  • RESULTS: Tumor cells staining for iNOS, NTYR and 8-OH-dG were detected in 41%, 62% and 50% of infiltrative carcinoma, respectively.
  • The three markers were shown for the first time in intraepithelial carcinoma.
  • The expression of iNOS was significantly more frequent in tubular carcinoma (TC) compared to diffuse carcinoma (DC) (54% vs 18%; P = 0.008) or in polymorphous carcinoma (PolyC) (54% vs 21%; P = 0.04).
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Oxidative Stress. Stomach Neoplasms / metabolism. Stomach Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers / analysis. Carcinoma in Situ / chemistry. Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. DNA, Neoplasm / metabolism. Deoxyguanine Nucleotides / analysis. Female. Gastric Mucosa / chemistry. Gastric Mucosa / metabolism. Gastric Mucosa / pathology. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Proteins / analysis. Nitric Oxide / metabolism. Nitric Oxide Synthase Type II / metabolism. Precancerous Conditions / chemistry. Precancerous Conditions / pathology. Precancerous Conditions / physiopathology. Retrospective Studies. Tyrosine / analogs & derivatives. Tyrosine / analysis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] APMIS. 1993 Apr;101(4):330-6 [7686760.001]
  • [Cites] Biochem Biophys Res Commun. 1992 Sep 30;187(3):1291-7 [1384469.001]
  • [Cites] Int J Cancer. 1994 Sep 15;58(6):825-9 [7523311.001]
  • [Cites] FEBS Lett. 1995 Jan 16;358(1):1-3 [7821417.001]
  • [Cites] Cancer Res. 2000 Jan 1;60(1):184-90 [10646872.001]
  • [Cites] Cancer Lett. 1999 Nov 15;146(2):173-80 [10656623.001]
  • [Cites] Am J Surg Pathol. 2000 Feb;24(2):167-76 [10680883.001]
  • [Cites] Clin Cancer Res. 2000 Apr;6(4):1394-400 [10778969.001]
  • [Cites] Prostate. 2000 Jul 1;44(2):144-55 [10881024.001]
  • [Cites] Gut. 2000 Aug;47(2):251-5 [10896917.001]
  • [Cites] Helicobacter. 2001 Mar;6(1):37-43 [11328364.001]
  • [Cites] Dig Dis Sci. 2001 Apr;46(4):836-44 [11330421.001]
  • [Cites] Clin Cancer Res. 2001 May;7(5):1325-32 [11350902.001]
  • [Cites] Am J Gastroenterol. 2001 Jun;96(6):1758-66 [11419826.001]
  • [Cites] Cancer Lett. 2001 Oct 30;172(2):177-85 [11566494.001]
  • [Cites] J Clin Gastroenterol. 2001 Nov-Dec;33(5):383-8 [11606854.001]
  • [Cites] World J Gastroenterol. 2002 Aug;8(4):591-5 [12174362.001]
  • [Cites] BMC Cancer. 2002 Apr 29;2:8 [11978184.001]
  • [Cites] Helicobacter. 2002 Dec;7(6):342-8 [12485120.001]
  • [Cites] Eur J Cancer. 2003 Jun;39(9):1296-301 [12763220.001]
  • [Cites] Arch Biochem Biophys. 2003 Sep 1;417(1):3-11 [12921773.001]
  • [Cites] J Clin Pathol. 2003 Sep;56(9):699-702 [12944556.001]
  • [Cites] Gynecol Oncol. 2004 Mar;92(3):806-12 [14984945.001]
  • [Cites] Am J Surg Pathol. 1995;19 Suppl 1:S37-43 [7762738.001]
  • [Cites] Cancer Res. 1996 Mar 15;56(6):1279-82 [8640814.001]
  • [Cites] Am J Surg Pathol. 1996;20 Suppl 1:S8-22 [8694148.001]
  • [Cites] Cancer Res. 1996 Jul 15;56(14):3238-43 [8764115.001]
  • [Cites] Am J Surg Pathol. 1996 Oct;20(10):1161-81 [8827022.001]
  • [Cites] J Invest Dermatol. 1996 Nov;107(5):733-7 [8875958.001]
  • [Cites] Lab Invest. 1997 Mar;76(3):365-74 [9121119.001]
  • [Cites] FEBS Lett. 1997 Jul 14;411(2-3):157-60 [9271196.001]
  • [Cites] J Biol Chem. 1997 Aug 8;272(32):19633-6 [9289489.001]
  • [Cites] Carcinogenesis. 1997 Sep;18(9):1841-5 [9328184.001]
  • [Cites] Am J Gastroenterol. 1997 Oct;92(10):1853-7 [9382051.001]
  • [Cites] Mutat Res. 1997 Dec;387(3):147-63 [9439711.001]
  • [Cites] Cancer Lett. 1998 Mar 13;125(1-2):61-8 [9566697.001]
  • [Cites] Gut. 1998 Mar;42(3):351-6 [9577340.001]
  • [Cites] Hum Pathol. 1998 Jul;29(7):702-9 [9670827.001]
  • [Cites] Cancer Res. 1998 Jul 15;58(14):2929-34 [9679948.001]
  • [Cites] Aliment Pharmacol Ther. 1998 Feb;12 Suppl 1:25-36 [9701002.001]
  • [Cites] Eur J Cancer Prev. 1998 Dec;7(6):439-47 [9926291.001]
  • [Cites] Clin Cancer Res. 1999 Jun;5(6):1411-5 [10389926.001]
  • [Cites] Free Radic Biol Med. 1999 Aug;27(3-4):401-10 [10468215.001]
  • [Cites] Cancer Lett. 1999 Oct 1;144(2):161-7 [10529016.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] World J Gastroenterol. 2004 Jul 1;10(13):1918-22 [15222037.001]
  • [Cites] World J Gastroenterol. 2004 Aug 1;10(15):2232-40 [15259072.001]
  • [Cites] Food Chem Toxicol. 1990 Sep;28(9):647-52 [2272563.001]
  • [Cites] Gut. 1994 Feb;35(2):179-85 [8307467.001]
  • (PMID = 16534838.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers; 0 / DNA, Neoplasm; 0 / Deoxyguanine Nucleotides; 0 / Neoplasm Proteins; 31C4KY9ESH / Nitric Oxide; 3604-79-3 / 3-nitrotyrosine; 42HK56048U / Tyrosine; EC 1.14.13.39 / Nitric Oxide Synthase Type II
  • [Other-IDs] NLM/ PMC4087889
  •  go-up   go-down


91. Khayat AS, Guimarães AC, Calcagno DQ, Seabra AD, Lima EM, Leal MF, Faria MH, Rabenhorst SH, Assumpção PP, Demachki S, Smith MA, Burbano RR: Interrelationship between TP53 gene deletion, protein expression and chromosome 17 aneusomy in gastric adenocarcinoma. BMC Gastroenterol; 2009;9:55
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interrelationship between TP53 gene deletion, protein expression and chromosome 17 aneusomy in gastric adenocarcinoma.
  • BACKGROUND: This study evaluates the existence of numerical alterations of chromosome 17 and TP53 gene deletion in gastric adenocarcinoma.
  • The frequency of cells with two chr17 and one TP53 signals observed was higher in diffuse than in intestinal-type GC.
  • Immunoreactivity of p53 was found only in intestinal-type samples.
  • The frequency of cells with two chr17 and two TP53 signals found was higher in samples with positive p53 expression than in negative cases in intestinal-type GC.
  • CONCLUSION: We suggest that TP53 deletion and chromosome 17 aneusomy is a common event in GC and other TP53 alterations, as mutation, may be implicated in the distinct carcinogenesis process of diffuse and intestinal types.
  • [MeSH-major] Adenocarcinoma / genetics. Chromosome Aberrations. Chromosomes, Human, Pair 17 / genetics. Gene Deletion. Gene Expression Regulation, Neoplastic / genetics. Stomach Neoplasms / genetics. Tumor Suppressor Protein p53 / genetics

  • Genetic Alliance. consumer health - Chromosome 17, Deletion.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 2000 Sep;37(3):241-9 [10971700.001]
  • [Cites] Cancer Genet Cytogenet. 2009 Apr 1;190(1):1-7 [19264226.001]
  • [Cites] Hum Mutat. 2003 Mar;21(3):258-70 [12619111.001]
  • [Cites] Acta Biochim Pol. 2003;50(1):231-8 [12673364.001]
  • [Cites] Lab Invest. 2003 Sep;83(9):1311-20 [13679439.001]
  • [Cites] Anticancer Res. 2004 Jan-Feb;24(1):155-9 [15015591.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Sep;153(2):127-32 [15350302.001]
  • [Cites] Mod Pathol. 2004 Nov;17(11):1328-37 [15154013.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 May;83(9):2934-8 [3458254.001]
  • [Cites] Cancer Genet Cytogenet. 1986 Aug;22(4):295-307 [3731046.001]
  • [Cites] Cancer Genet Cytogenet. 1987 Jan;24(1):63-73 [3791173.001]
  • [Cites] Histochemistry. 1988;89(4):307-16 [3410743.001]
  • [Cites] Cancer. 1990 Aug 1;66(3):491-7 [2364362.001]
  • [Cites] Virchows Arch. 1995;426(5):447-55 [7633655.001]
  • [Cites] Int J Cancer. 1996 May 29;66(5):594-9 [8647618.001]
  • [Cites] Cancer. 1995 Sep 1;76(5):720-6 [8625172.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jul 9;93(14):7081-4 [8692948.001]
  • [Cites] Am J Pathol. 1996 Nov;149(5):1575-84 [8909247.001]
  • [Cites] Cancer Genet Cytogenet. 1996 Dec;92(2):122-9 [8976368.001]
  • [Cites] Nihon Ika Daigaku Zasshi. 1997 Feb;64(1):22-9 [9119949.001]
  • [Cites] Oncology. 1997 Mar-Apr;54(2):166-70 [9075790.001]
  • [Cites] Cancer Genet Cytogenet. 1998 Apr 1;102(1):88-90 [9530349.001]
  • [Cites] Nature. 1998 Dec 17;396(6712):643-9 [9872311.001]
  • [Cites] Am J Phys Anthropol. 1999 Jun;109(2):175-80 [10378456.001]
  • [Cites] J Int Med Res. 1999 Mar-Apr;27(2):85-9 [10446695.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2005 Apr;40(4):467-70 [15795596.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Jun 10;331(3):694-700 [15865924.001]
  • [Cites] Br J Cancer. 2005 May 9;92(9):1759-66 [15827559.001]
  • [Cites] Anticancer Res. 2005 Nov-Dec;25(6B):4069-74 [16309200.001]
  • [Cites] Cancer Genet Cytogenet. 2006 Aug;169(1):45-9 [16875936.001]
  • [Cites] Anticancer Res. 2006 Jul-Aug;26(4B):2909-14 [16886612.001]
  • [Cites] World J Gastroenterol. 2006 Oct 14;12(38):6207-11 [17036397.001]
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):3139-46 [10955795.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Aug;121(1):38-43 [10958939.001]
  • [Cites] Clin Exp Med. 2006 Oct;6(3):129-33 [17061062.001]
  • [Cites] Cancer Biol Ther. 2006 Sep;5(9):1154-60 [16855375.001]
  • [Cites] Arq Gastroenterol. 2006 Jul-Sep;43(3):247-51 [17160244.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2008 Jan;16(1):13-8 [18091326.001]
  • [Cites] Cancer Lett. 2008 Aug 8;266(2):99-115 [18381231.001]
  • [Cites] Lab Invest. 2000 Oct;80(10):1501-8 [11045566.001]
  • (PMID = 19619279.001).
  • [ISSN] 1471-230X
  • [Journal-full-title] BMC gastroenterology
  • [ISO-abbreviation] BMC Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ PMC2716360
  •  go-up   go-down


92. Soini Y, Tommola S, Helin H, Martikainen P: Claudins 1, 3, 4 and 5 in gastric carcinoma, loss of claudin expression associates with the diffuse subtype. Virchows Arch; 2006 Jan;448(1):52-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Claudins 1, 3, 4 and 5 in gastric carcinoma, loss of claudin expression associates with the diffuse subtype.
  • In this study expression of claudins 1, 3, 4 and 5 were studied in 118 cases of gastric carcinoma and compared with proliferation, apoptosis and E-cadherin expression.
  • Expression of all these claudins could be seen in gastric carcinoma, most prominently for claudin 4, and least expression was found for claudin 5.
  • All claudins showed significantly more expression in gastric carcinomas of intestinal type.
  • Claudin 3 expression had an association with a better prognosis of the patients, especially in the intestinal type.
  • The results show that expression of claudins 1, 3, 4 and 5 is lower in diffuse-type gastric carcinomas.
  • Possibly they play a role in determining the diffuse phenotype and loose cohesion of cells in diffuse type of gastric carcinoma in a similar manner as E-cadherin.
  • The loss of their expression does not clearly associate with poorer prognosis of the patients, except for claudin 3, where strong expression was associated with a better outcome of the patients, a feature especially related to intestinal-type tumours.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Membrane Proteins / biosynthesis. Stomach Neoplasms / metabolism. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16220299.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / Ki-67 Antigen; 0 / Membrane Proteins
  •  go-up   go-down


93. Kano MR, Bae Y, Iwata C, Morishita Y, Yashiro M, Oka M, Fujii T, Komuro A, Kiyono K, Kaminishi M, Hirakawa K, Ouchi Y, Nishiyama N, Kataoka K, Miyazono K: Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-beta signaling. Proc Natl Acad Sci U S A; 2007 Feb 27;104(9):3460-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, we present an application of a short-acting, small-molecule TGF-beta type I receptor (TbetaR-I) inhibitor at a low dose in treating several experimental intractable solid tumors, including pancreatic adenocarcinoma and diffuse-type gastric cancer, characterized by hypovascularity and thick fibrosis in tumor microenvironments.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Med. 2003 Jun;9(6):713-25 [12778170.001]
  • [Cites] J Drug Target. 2002 Nov;10(7):539-48 [12683721.001]
  • [Cites] J Med Chem. 2003 Sep 11;46(19):3953-6 [12954047.001]
  • [Cites] J Cell Biol. 2003 Dec 22;163(6):1303-11 [14676305.001]
  • [Cites] Cancer Res. 2003 Dec 15;63(24):8977-83 [14695216.001]
  • [Cites] Lancet Oncol. 2004 Sep;5(9):541-9 [15337483.001]
  • [Cites] Technol Cancer Res Treat. 2004 Oct;3(5):451-7 [15453810.001]
  • [Cites] Cancer Res. 1986 Dec;46(12 Pt 1):6387-92 [2946403.001]
  • [Cites] Crit Rev Ther Drug Carrier Syst. 1989;6(3):193-210 [2692843.001]
  • [Cites] N Engl J Med. 1995 Jul 6;333(1):32-41 [7776992.001]
  • [Cites] Clin Exp Metastasis. 1996 Jan;14(1):43-54 [8521616.001]
  • [Cites] Pancreas. 1996 Nov;13(4):395-400 [8899800.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2403-13 [9196156.001]
  • [Cites] J Cell Biol. 1998 May 4;141(3):805-14 [9566978.001]
  • [Cites] Gynecol Oncol. 1998 Sep;70(3):351-7 [9790787.001]
  • [Cites] Clin Cancer Res. 1996 Oct;2(10):1679-84 [9816116.001]
  • [Cites] Science. 1999 May 28;284(5419):1534-7 [10348742.001]
  • [Cites] Nat Rev Drug Discov. 2004 Dec;3(12):1011-22 [15573100.001]
  • [Cites] Bioconjug Chem. 2005 Jan-Feb;16(1):122-30 [15656583.001]
  • [Cites] Cardiovasc Res. 2005 Feb 15;65(3):599-608 [15664386.001]
  • [Cites] Nat Rev Cancer. 2005 Mar;5(3):161-71 [15738981.001]
  • [Cites] Br J Cancer. 2005 Apr 11;92(7):1240-6 [15785749.001]
  • [Cites] J Gastroenterol. 2005 May;40(5):518-25 [15942718.001]
  • [Cites] J Cell Sci. 2005 Aug 15;118(Pt 16):3759-68 [16105884.001]
  • [Cites] Annu Rev Cell Dev Biol. 2005;21:659-93 [16212511.001]
  • [Cites] J Natl Cancer Inst. 2006 Mar 1;98(5):335-44 [16507830.001]
  • [Cites] Clin Med Res. 2006 Mar;4(1):66-78 [16595794.001]
  • [Cites] Cancer Res. 2006 Jul 1;66(13):6714-21 [16818646.001]
  • [Cites] Nat Rev Cancer. 2006 Sep;6(9):688-701 [16900224.001]
  • [Cites] Dev Biol. 2000 Jan 1;217(1):42-53 [10625534.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2626-31 [10716993.001]
  • [Cites] Nat Genet. 2000 Nov;26(3):328-31 [11062473.001]
  • [Cites] Curr Oncol Rep. 2001 Mar;3(2):156-62 [11177748.001]
  • [Cites] Adv Drug Deliv Rev. 2001 Mar 23;47(1):113-31 [11251249.001]
  • [Cites] EMBO J. 2001 Apr 2;20(7):1663-73 [11285230.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8621-3 [12861075.001]
  • (PMID = 17307870.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ly-364947; 0 / Pyrazoles; 0 / Pyrroles; 0 / Receptors, Transforming Growth Factor beta; 0 / Transforming Growth Factor beta; EC 2.7.1.11 / TGF-beta type I receptor; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  • [Other-IDs] NLM/ PMC1800736
  •  go-up   go-down


94. Chatterjee D, Sabo E, Tavares R, Resnick MB: Inverse association between Raf Kinase Inhibitory Protein and signal transducers and activators of transcription 3 expression in gastric adenocarcinoma patients: implications for clinical outcome. Clin Cancer Res; 2008 May 15;14(10):2994-3001
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inverse association between Raf Kinase Inhibitory Protein and signal transducers and activators of transcription 3 expression in gastric adenocarcinoma patients: implications for clinical outcome.
  • RESULTS: In intestinal-type gastric adenocarcinomas, RKIP and STAT3, expression were inversely associated.
  • In the diffuse tumor type, no significant correlation was found between RKIP and patient outcome.
  • In the intestinal-type gastric adenocarcinoma, multivariate analysis adjusted for treatment types revealed RKIP and tumor stage to be significant independent predictors of survival.
  • In the diffuse tumor type, stage was the only significant predictor of survival.
  • CONCLUSION: These results indicate the predictive and protective role of cytoplasmic RKIP expression in gastric adenocarcinoma of the intestinal subtype.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / analysis. Phosphatidylethanolamine Binding Protein / biosynthesis. STAT3 Transcription Factor / biosynthesis. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18483365.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / P20 RR17695
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / PEBP1 protein, human; 0 / Phosphatidylethanolamine Binding Protein; 0 / STAT3 Transcription Factor
  •  go-up   go-down


95. Vang R, Vinh TN, Burks RT, Barner R, Kurman RJ, Ronnett BM: Pseudoinfiltrative tubal metaplasia of the endocervix: a potential form of in utero diethylstilbestrol exposure-related adenosis simulating minimal deviation adenocarcinoma. Int J Gynecol Pathol; 2005 Oct;24(4):391-8
Hazardous Substances Data Bank. DIETHYLSTILBESTROL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudoinfiltrative tubal metaplasia of the endocervix: a potential form of in utero diethylstilbestrol exposure-related adenosis simulating minimal deviation adenocarcinoma.
  • We report three cases of unusual tubal-type endocervical glandular proliferations simulating minimal deviation adenocarcinoma in women with a history of in utero diethylstilbestrol (DES) exposure.
  • The glandular epithelium displayed extensive tubal-type differentiation in all cases.
  • Immunohistochemical studies showed diffuse expression of estrogen and progesterone receptors and essentially no expression of p16 in two cases tested; there was no expression of CD10 in one case that was tested.
  • The proliferations lacked features of mucinous and tubo-endometrioid types of minimal deviation adenocarcinoma.
  • [MeSH-major] Adenocarcinoma. Cervix Uteri / pathology. Diethylstilbestrol / adverse effects. Uterine Cervical Neoplasms

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16175088.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 731DCA35BT / Diethylstilbestrol
  •  go-up   go-down


96. Zheng H, Takahashi H, Murai Y, Cui Z, Nomoto K, Miwa S, Tsuneyama K, Takano Y: Pathobiological characteristics of intestinal and diffuse-type gastric carcinoma in Japan: an immunostaining study on the tissue microarray. J Clin Pathol; 2007 Mar;60(3):273-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathobiological characteristics of intestinal and diffuse-type gastric carcinoma in Japan: an immunostaining study on the tissue microarray.
  • AIM: To investigate the pathobiological features of intestinal and diffuse-type gastric carcinomas in the Japanese population.
  • METHODS: The expression of fragile histine triad (FHIT), phosphatase and tensin homology deleted from human chromosome 10 (PTEN), caspase-3, Ki-67, mutant p53, matrix metalloproteinase (MMP)-2, MMP-9, and extracellular matrix metalloproteinase inducer (EMMPRIN) on tissue microarrays of gastric carcinomas by immunostaining was examined in comparison with the clinicopathological characteristics between intestinal and diffuse-type cases.
  • RESULTS: Intestinal-type carcinoma frequently occurred in old men, whereas the diffuse type comparatively occurred more in young women (p<0.05).
  • The diffuse-type carcinoma was more inclined to invasion into muscularis propria, lymphatic invasion and lymph node metastasis, and belonged to higher International Union against Cancer (UICC) staging (p<0.05) compared with intestinal-type counterparts.
  • Expression of FHIT, PTEN, Ki-67, caspase-3, mutant p53 and EMPPRIN was higher in intestinal-type carcinomas than in diffuse-type carcinomas (p<0.05).
  • Kaplan-Meier analysis indicated that patients with intestinal-type carcinomas had a higher cumulative survival rate (p<0.05).
  • CONCLUSION: Intestinal-type gastric carcinomas with a more favourable prognosis frequently show high levels of proliferation and apoptosis, and always accompany strong expression of FHIT, PTEN and mutant p53 and EMMPRIN.
  • EMMPRIN expression might underlie the molecular basis of liver metastasis and higher proliferation of intestinal-type gastric carcinomas in Japan.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Biol Ther. 2002 May-Jun;1(3):232-6 [12432269.001]
  • [Cites] J Exp Clin Cancer Res. 2002 Sep;21(3):371-5 [12385580.001]
  • [Cites] World J Gastroenterol. 2003 Jul;9(7):1415-20 [12854132.001]
  • [Cites] Pathol Int. 2003 Oct;53(10):659-66 [14516315.001]
  • [Cites] Cancer Res. 2004 Feb 15;64(4):1229-32 [14983875.001]
  • [Cites] World J Gastroenterol. 2004 Mar 1;10(5):750-4 [14991954.001]
  • [Cites] IARC Sci Publ. 2004;(157):301-10 [15055303.001]
  • [Cites] Mod Pathol. 2004 Sep;17(9):1141-9 [15167936.001]
  • [Cites] Gan. 1968 Jun;59(3):251-8 [5726267.001]
  • [Cites] Cancer. 1990 May 1;65(9):2086-90 [2372774.001]
  • [Cites] Eur J Cancer. 1992;28A(10):1642-6 [1389480.001]
  • [Cites] J Clin Gastroenterol. 1997 Dec;25(4):646-9 [9451680.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Science. 2004 Nov 26;306(5701):1568-71 [15567866.001]
  • [Cites] Biochimie. 2005 Mar-Apr;87(3-4):361-8 [15781323.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3193-9 [15833850.001]
  • [Cites] Br J Surg. 2005 Nov;92(11):1331-2 [16240283.001]
  • [Cites] J Biol Chem. 2006 Apr 7;281(14):9719-27 [16443928.001]
  • [Cites] J Cell Physiol. 2000 Mar;182(3):311-22 [10653597.001]
  • [Cites] J Clin Epidemiol. 2003 Jan;56(1):1-9 [12589864.001]
  • (PMID = 16714395.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BSG protein, human; 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Neoplasm Proteins; 0 / Tumor Suppressor Protein p53; 0 / fragile histidine triad protein; 136894-56-9 / Antigens, CD147; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase; EC 3.4.22.- / Caspase 3; EC 3.6.- / Acid Anhydride Hydrolases
  • [Other-IDs] NLM/ PMC1860577
  •  go-up   go-down


97. Gigek CO, Leal MF, Lisboa LC, Silva PN, Chen ES, Lima EM, Calcagno DQ, Assumpção PP, Burbano RR, Smith Mde A: Insulin-like growth factor binding protein-3 gene methylation and protein expression in gastric adenocarcinoma. Growth Horm IGF Res; 2010 Jun;20(3):234-8
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Insulin-like growth factor binding protein-3 gene methylation and protein expression in gastric adenocarcinoma.
  • DESIGN: Forty-three normal gastric mucosa and 94 adenocarcinoma samples were investigated through methylation specific PCR, after bisulfite modification.
  • Intestinal type presented a higher frequency of protein expression than diffuse type (p=0.0412).
  • [MeSH-major] Adenocarcinoma. DNA Methylation. Insulin-Like Growth Factor Binding Protein 3 / genetics. Insulin-Like Growth Factor Binding Protein 3 / metabolism. Stomach Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20219400.001).
  • [ISSN] 1532-2238
  • [Journal-full-title] Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society
  • [ISO-abbreviation] Growth Horm. IGF Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Insulin-Like Growth Factor Binding Protein 3; 0 / Proteins
  •  go-up   go-down


98. Miyahara R, Niwa Y, Matsuura T, Maeda O, Ando T, Ohmiya N, Itoh A, Hirooka Y, Goto H: Prevalence and prognosis of gastric cancer detected by screening in a large Japanese population: data from a single institute over 30 years. J Gastroenterol Hepatol; 2007 Sep;22(9):1435-42
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We studied the prevalence of gastric carcinoma, its prognosis, differences between the two histological types of carcinoma and historical changes.
  • Comparing two histological types, diffuse-type carcinoma cases relatively increased.
  • Intestinal-type carcinomas increased in the lower portion of the stomach, whereas diffuse-type increased in the upper portion.
  • The 5-year survival rate was 92.7% for intestinal-type carcinoma and 84.8% for diffuse-type.
  • Diffuse-type carcinomas were further progressed than intestinal-type when detected by direct radiology; however, detection of diffuse-type improved, so the percentage of early gastric cancer of diffuse type significantly increased, and the survival rate significantly improved, from 70.4% to 90.5%.
  • CONCLUSION: The prevalence of gastric cancer has been decreasing, but the proportion of diffuse-type carcinoma localized in the upper portion of the stomach has been increasing in Japan.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17573829.001).
  • [ISSN] 0815-9319
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


99. Satoh A, Shuto K, Okazumi S, Ohira G, Natsume T, Hayano K, Narushima K, Saito H, Ohta T, Nabeya Y, Yanagawa N, Matsubara H: Role of perfusion CT in assessing tumor blood flow and malignancy level of gastric cancer. Dig Surg; 2010;27(4):253-60
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cases with Lauren's diffuse type carcinoma were found to have decreased blood flow compared to the mixed or intestinal type.

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 S. Karger AG, Basel.
  • (PMID = 20668380.001).
  • [ISSN] 1421-9883
  • [Journal-full-title] Digestive surgery
  • [ISO-abbreviation] Dig Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  •  go-up   go-down


100. Zakharov V, Lin HK, Azzarello J, McMeekin S, Moore KN, Penning TM, Fung KM: Suppressed expression of type 2 3alpha/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) in endometrial hyperplasia and carcinoma. Int J Clin Exp Pathol; 2010 Jul 05;3(6):608-17
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Suppressed expression of type 2 3alpha/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) in endometrial hyperplasia and carcinoma.
  • The diagnosis of endometrial hyperplasia and endometrial type adenocarcinoma arising within the uterine cavity has long been rested on morphologic criteria.
  • Although distinction between normal endometrial epithelium from adenocarcinoma is usually straightforward, the separation between normal and hyperplastic endometrium, particularly those cases without atypia, can be a diagnostic challenge.
  • The same is true in separation of hyperplastic endometrium with atypia from endometrial-type endometrial adenocarcinoma.
  • Type 2 3alpha-/type 5 17beta-hydroxysteroid dehydrogenase (HSD) (AKR1C3) is a multifunctional enzyme involved in androgen, estrogen, progesterone, and pros-taglandin metabolism.
  • Its expression has been shown in the epithelium of the renal tubules, urothelial epithelium, and endothelial cells in normal tissues as well as in prostatic adenocarcinoma.
  • We studied the expression of AKR1C3 in 33 endometrial biopsy specimens including 13 cases of normal proliferative endometrium, 8 cases of hyperplastic endometrium with and without atypia, and 12 cases of primary endometrial adenocarcinoma of endometrial type.
  • We demonstrated a uniform, diffuse, and strong expression of AKR1C3 in normal endometrial epithelium but not in endometrial stromal cells.
  • However, reduced AKR1C3 expression cannot distinguish hyperplastic endometrium from endometrial adenocarcinoma of endometrial type.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BMC Cancer. 2004 Jun 22;4:27 [15212687.001]
  • [Cites] J Cancer Res Clin Oncol. 2003 Apr;129(4):245-9 [12695909.001]
  • [Cites] Lancet. 1991 Aug 3;338(8762):274-7 [1677110.001]
  • [Cites] J Biol Chem. 1993 Jun 15;268(17):12964-9 [8099587.001]
  • [Cites] Biochem J. 1994 Apr 15;299 ( Pt 2):545-52 [8172617.001]
  • [Cites] Am J Pathol. 1995 Feb;146(2):491-500 [7856758.001]
  • [Cites] J Biol Chem. 1995 Aug 25;270(34):20162-8 [7650035.001]
  • [Cites] Cell. 1995 Dec 1;83(5):803-12 [8521497.001]
  • [Cites] Biochem J. 1996 Jan 15;313 ( Pt 2):373-6 [8573067.001]
  • [Cites] Biochem Biophys Res Commun. 1996 Nov 12;228(2):474-9 [8920937.001]
  • [Cites] Mol Endocrinol. 1997 Jan;11(1):77-86 [8994190.001]
  • [Cites] Biochem J. 1997 Sep 15;326 ( Pt 3):625-36 [9307009.001]
  • [Cites] Biochem Pharmacol. 1997 Sep 15;54(6):639-47 [9310340.001]
  • [Cites] Mol Endocrinol. 1997 Dec;11(13):1971-84 [9415401.001]
  • [Cites] J Biochem. 1998 Nov;124(5):940-6 [9792917.001]
  • [Cites] Endocrinology. 1999 Feb;140(2):568-74 [9927279.001]
  • [Cites] Carcinogenesis. 2004 Nov;25(11):2177-81 [15284179.001]
  • [Cites] Steroids. 2004 Dec;69(13-14):795-801 [15582534.001]
  • [Cites] Endocr Relat Cancer. 2005 Mar;12(1):101-7 [15788642.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7707-16 [16140938.001]
  • [Cites] Endocr Relat Cancer. 2005 Dec;12(4):701-20 [16322318.001]
  • [Cites] Mol Endocrinol. 2006 Jan;20(1):35-44 [16123151.001]
  • [Cites] Cancer Res. 2006 Mar 1;66(5):2815-25 [16510604.001]
  • [Cites] Mol Cell Endocrinol. 2006 Mar 27;248(1-2):126-35 [16338060.001]
  • [Cites] Mol Cell Endocrinol. 2006 Mar 27;248(1-2):136-40 [16406263.001]
  • [Cites] Mol Cell Endocrinol. 2006 Mar 27;248(1-2):182-91 [16417966.001]
  • [Cites] Endocr Relat Cancer. 2006 Mar;13(1):169-80 [16601286.001]
  • [Cites] Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4200-8 [16857792.001]
  • [Cites] BJOG. 2008 Jan;115(1):113-7 [17983420.001]
  • [Cites] Endocr J. 2007 Dec;54(5):667-79 [17785917.001]
  • [Cites] J Clin Pathol. 2008 Apr;61(4):448-54 [17720776.001]
  • [Cites] J Histochem Cytochem. 2008 Sep;56(9):853-61 [18574251.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Sep;93(9):3471-7 [18559914.001]
  • [Cites] Mol Cell Endocrinol. 2009 Mar 25;301(1-2):74-82 [18930784.001]
  • [Cites] Int J Clin Exp Pathol. 2009;3(2):147-55 [20126582.001]
  • [Cites] Urology. 2010 Jul;76(1):67-72 [19942269.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Jul;86(7):3436-43 [11443221.001]
  • [Cites] J Mol Endocrinol. 2000 Feb;24(1):135-44 [10657005.001]
  • [Cites] Biochem J. 2000 Oct 1;351(Pt 1):67-77 [10998348.001]
  • [Cites] Am J Obstet Gynecol. 2001 Feb;184(3):303-8 [11228478.001]
  • [Cites] Mol Endocrinol. 2001 Dec;15(12):2093-105 [11731611.001]
  • [Cites] Chem Biol Interact. 2003 Feb 1;143-144:621-31 [12604248.001]
  • [Cites] J Clin Endocrinol Metab. 1975 Mar;40(3):367-72 [234975.001]
  • (PMID = 20661409.001).
  • [ISSN] 1936-2625
  • [Journal-full-title] International journal of clinical and experimental pathology
  • [ISO-abbreviation] Int J Clin Exp Pathol
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / P30 ES013508; United States / NCI NIH HHS / CA / R01 CA090744; United States / NCI NIH HHS / CA / 1R01-CA90744; United States / NIEHS NIH HHS / ES / P30-ES013508
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 1.1.- / 3-Hydroxysteroid Dehydrogenases; EC 1.1.1.- / AKR1C3 protein, human; EC 1.1.1.- / Hydroxyprostaglandin Dehydrogenases
  • [Other-IDs] NLM/ PMC2907123
  • [Keywords] NOTNLM ; Aldo-keto reductase / endomtrial cancer / estrogen / progesterone / prostaglandin
  •  go-up   go-down






Advertisement